Craig W Lindsley

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7261207/publications.pdf

Version: 2024-02-01

		14653	22829
633	18,889	66	112
papers	citations	h-index	g-index

659	659	659	15845
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nature Reviews Drug Discovery, 2009, 8, 41-54.	46.4	929
2	Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 761-764.	2.2	479
3	Efficient Synthesis of Imidazoles from Aldehydes and 1,2-Diketones Using Microwave Irradiation. Organic Letters, 2004, 6, 1453-1456.	4.6	382
4	In Vivo Structureâ"Activity Relationship Study of Dorsomorphin Analogues Identifies Selective VEGF and BMP Inhibitors. ACS Chemical Biology, 2010, 5, 245-253.	3.4	361
5	Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. Trends in Pharmacological Sciences, 2009, 30, 25-31.	8.7	325
6	A Novel Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Has in Vivo Activity and Antipsychotic-Like Effects in Rat Behavioral Models. Journal of Pharmacology and Experimental Therapeutics, 2005, 313, 199-206.	2.5	289
7	Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders. Trends in Pharmacological Sciences, 2009, 30, 148-155.	8.7	258
8	Selective activation of the M ₁ muscarinic acetylcholine receptor achieved by allosteric potentiation. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 15950-15955.	7.1	253
9	A Family of Highly Selective Allosteric Modulators of the Metabotropic Glutamate Receptor Subtype 5. Molecular Pharmacology, 2003, 64, 731-740.	2.3	226
10	Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders. Nature Reviews Drug Discovery, 2014, 13, 692-708.	46.4	226
11	Novel Selective Allosteric Activator of the M₁Muscarinic Acetylcholine Receptor Regulates Amyloid Processing and Produces Antipsychotic-Like Activity in Rats. Journal of Neuroscience, 2008, 28, 10422-10433.	3.6	219
12	Drugs for Allosteric Sites on Receptors. Annual Review of Pharmacology and Toxicology, 2014, 54, 165-184.	9.4	218
13	A Selective Allosteric Potentiator of the M₁Muscarinic Acetylcholine Receptor Increases Activity of Medial Prefrontal Cortical Neurons and Restores Impairments in Reversal Learning. Journal of Neuroscience, 2009, 29, 14271-14286.	3.6	217
14	Allosteric Modulation of Seven Transmembrane Spanning Receptors: Theory, Practice, and Opportunities for Central Nervous System Drug Discovery. Journal of Medicinal Chemistry, 2012, 55, 1445-1464.	6.4	212
15	Phospholipase D Signaling Pathways and Phosphatidic Acid as Therapeutic Targets in Cancer. Pharmacological Reviews, 2014, 66, 1033-1079.	16.0	209
16	Application of Combinatorial Chemistry Science on Modern Drug Discovery. ACS Combinatorial Science, 2008, 10, 345-354.	3.3	206
17	mGluR5 Positive Allosteric Modulators Facilitate both Hippocampal LTP and LTD and Enhance Spatial Learning. Neuropsychopharmacology, 2009, 34, 2057-2071.	5.4	199
18	Discovery, Characterization, and Antiparkinsonian Effect of Novel Positive Allosteric Modulators of Metabotropic Glutamate Receptor 4. Molecular Pharmacology, 2008, 74, 1345-1358.	2.3	187

#	Article	IF	Citations
19	M4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced Dyskinesia. Neuron, 2015, 88, 762-773.	8.1	183
20	Centrally Active Allosteric Potentiators of the M₄ Muscarinic Acetylcholine Receptor Reverse Amphetamine-Induced Hyperlocomotor Activity in Rats. Journal of Pharmacology and Experimental Therapeutics, 2008, 327, 941-953.	2.5	177
21	Discovery of Novel Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5 Reveals Chemical and Functional Diversity and In Vivo Activity in Rat Behavioral Models of Anxiolytic and Antipsychotic Activity. Molecular Pharmacology, 2010, 78, 1105-1123.	2.3	176
22	A Novel Selective Allosteric Modulator Potentiates the Activity of Native Metabotropic Glutamate Receptor Subtype 5 in Rat Forebrain. Journal of Pharmacology and Experimental Therapeutics, 2004, 309, 568-577.	2.5	175
23	Discovery of Positive Allosteric Modulators for the Metabotropic Glutamate Receptor Subtype 5 from a Series of N-(1,3-Diphenyl-1H- pyrazol-5-yl)benzamides That Potentiate Receptor Function in Vivo. Journal of Medicinal Chemistry, 2004, 47, 5825-5828.	6.4	164
24	Targeting phospholipase D in cancer, infection and neurodegenerative disorders. Nature Reviews Drug Discovery, 2017, 16, 351-367.	46.4	161
25	â€œMolecular Switchesâ€•on mGluR Allosteric Ligands That Modulate Modes of Pharmacology. Biochemistry, 2011, 50, 2403-2410.	2.5	155
26	G-Protein-Coupled Receptors: From Classical Modes of Modulation to Allosteric Mechanisms. ACS Chemical Biology, 2008, 3, 530-541.	3.4	154
27	Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors. Chemical Reviews, 2016, 116, 6707-6741.	47.7	151
28	Progress Towards Validating the NMDA Receptor Hypofunction Hypothesis of Schizophrenia. Current Topics in Medicinal Chemistry, 2006, 6, 771-785.	2.1	140
29	Discovery and Characterization of Novel Allosteric Potentiators of M₁Muscarinic Receptors Reveals Multiple Modes of Activity. Molecular Pharmacology, 2009, 75, 577-588.	2.3	135
30	ML297 (VU0456810), the First Potent and Selective Activator of the GIRK Potassium Channel, Displays Antiepileptic Properties in Mice. ACS Chemical Neuroscience, 2013, 4, 1278-1286.	3.5	135
31	Advancing Biological Understanding and Therapeutics Discovery with Small-Molecule Probes. Cell, 2015, 161, 1252-1265.	28.9	135
32	A Novel Selective Muscarinic Acetylcholine Receptor Subtype 1 Antagonist Reduces Seizures without Impairing Hippocampus-Dependent Learning. Molecular Pharmacology, 2009, 76, 356-368.	2.3	121
33	Biased mGlu 5 -Positive Allosteric Modulators Provide InÂVivo Efficacy without Potentiating mGlu 5 Modulation of NMDAR Currents. Neuron, 2015, 86, 1029-1040.	8.1	121
34	Selective Activation of M₄ Muscarinic Acetylcholine Receptors Reverses MK-801-Induced Behavioral Impairments and Enhances Associative Learning in Rodents. ACS Chemical Neuroscience, 2014, 5, 920-942.	3.5	116
35	The Ecstasy and Agony of Assay Interference Compounds. Journal of Medicinal Chemistry, 2017, 60, 2165-2168.	6.4	113
36	Functional Impact of Allosteric Agonist Activity of Selective Positive Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5 in Regulating Central Nervous System Function. Molecular Pharmacology, 2012, 81, 120-133.	2.3	112

#	Article	IF	Citations
37	Classics in Chemical Neuroscience: Clozapine. ACS Chemical Neuroscience, 2013, 4, 1018-1025.	3.5	111
38	Antipsychotic-like Effects of M 4 Positive Allosteric Modulators Are Mediated by CB 2 Receptor-Dependent Inhibition of Dopamine Release. Neuron, 2016, 91, 1244-1252.	8.1	110
39	Allosteric modulation of the M1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and Alzheimer's disease. Drug Discovery Today, 2013, 18, 1185-1199.	6.4	107
40	Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part I: Impact of alternative halogenated privileged structures for PLD1 specificity. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 1916-1920.	2.2	101
41	The Akt/PKB Family of Protein Kinases: A Review of Small Molecule Inhibitors and Progress Towards Target Validation: A 2009 Update. Current Topics in Medicinal Chemistry, 2010, 10, 458-477.	2.1	98
42	Novel Allosteric Agonists of M1 Muscarinic Acetylcholine Receptors Induce Brain Region-Specific Responses That Correspond with Behavioral Effects in Animal Models. Journal of Neuroscience, 2012, 32, 8532-8544.	3.6	98
43	The Metabotropic Glutamate Receptor 4-Positive Allosteric Modulator VU0364770 Produces Efficacy Alone and in Combination with l-DOPA or an Adenosine 2A Antagonist in Preclinical Rodent Models of Parkinson's Disease. Journal of Pharmacology and Experimental Therapeutics, 2012, 340, 404-421.	2.5	95
44	Unique Signaling Profiles of Positive Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5 Determine Differences in In Vivo Activity. Biological Psychiatry, 2013, 73, 501-509.	1.3	95
45	Rapid, General Access to Chiral Î²-Fluoroamines and Î²,Î²-Difluoroamines via Organocatalysis. Organic Letters, 2009, 11, 943-946.	4.6	93
46	Discovery of the First Highly M5-Preferring Muscarinic Acetylcholine Receptor Ligand, an M5 Positive Allosteric Modulator Derived from a Series of 5-Trifluoromethoxy N-Benzyl Isatins. Journal of Medicinal Chemistry, 2009, 52, 3445-3448.	6.4	92
47	Design, Synthesis, and Biological Evaluation of Halogenated N-(2-(4-Oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)ethyl)benzamides: Discovery of an Isoform-Selective Small Molecule Phospholipase D2 Inhibitor. Journal of Medicinal Chemistry, 2010, 53, 6706-6719.	6.4	92
48	Antipsychotic Drug-Like Effects of the Selective M4 Muscarinic Acetylcholine Receptor Positive Allosteric Modulator VU0152100. Neuropsychopharmacology, 2014, 39, 1578-1593.	5.4	91
49	Investigating Metabotropic Glutamate Receptor 5 Allosteric Modulator Cooperativity, Affinity, and Agonism: Enriching Structure-Function Studies and Structure-Activity Relationships. Molecular Pharmacology, 2012, 82, 860-875.	2.3	90
50	Discovery and Characterization of Novel Subtype-Selective Allosteric Agonists for the Investigation of M₁ Receptor Function in the Central Nervous System. ACS Chemical Neuroscience, 2010, 1, 104-121.	3.5	88
51	Metabotropic glutamate receptor 3 activation is required for long-term depression in medial prefrontal cortex and fear extinction. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 1196-1201.	7.1	86
52	The PI3K/Akt Pathway: Recent Progress in the Development of ATP-Competitive and Allosteric Akt Kinase Inhibitors. Current Cancer Drug Targets, 2008, 8, 7-18.	1.6	84
53	M4 mAChR-Mediated Modulation of Glutamatergic Transmission at Corticostriatal Synapses. ACS Chemical Neuroscience, 2014, 5, 318-324.	3.5	84
54	Schizophrenia: Moving Beyond Monoamine Antagonists. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2008, 8, 99-107.	3.4	82

#	Article	IF	Citations
55	Development of a Custom High-Throughput Preparative Liquid Chromatography/Mass Spectrometer Platform for the Preparative Purification and Analytical Analysis of Compound Libraries. ACS Combinatorial Science, 2003, 5, 322-329.	3.3	80
56	Synthesis and SAR of a mGluR5 allosteric partial antagonist lead: Unexpected modulation of pharmacology with slight structural modifications to a 5-(phenylethynyl)pyrimidine scaffold. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 4098-4101.	2.2	80
57	Allosteric modulation of kinases and GPCRs: design principles and structural diversity. Current Opinion in Chemical Biology, 2008, 12, 269-280.	6.1	80
58	The Discovery and Characterization of ML218: A Novel, Centrally Active T-Type Calcium Channel Inhibitor with Robust Effects in STN Neurons and in a Rodent Model of Parkinsonâ€™s Disease. ACS Chemical Neuroscience, 2011, 2, 730-742.	3.5	80
59	Synthesis and Evaluation of a Series of Heterobiarylamides That Are Centrally Penetrant Metabotropic Glutamate Receptor 4 (mGluR4) Positive Allosteric Modulators (PAMs). Journal of Medicinal Chemistry, 2009, 52, 4115-4118.	6.4	79
60	Functional partnership between mGlu3 and mGlu5 metabotropic glutamate receptors in the central nervous system. Neuropharmacology, 2018, 128, 301-313.	4.1	79
61	Further optimization of the K-Cl cotransporter KCC2 antagonist ML077: Development of a highly selective and more potent in vitro probe. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 4532-4535.	2.2	78
62	The Ecstasy and Agony of Assay Interference Compounds. ACS Central Science, 2017, 3, 143-147.	11.3	78
63	Allosteric Modulators for the Treatment of Schizophrenia: Targeting Glutamatergic Networks. Current Topics in Medicinal Chemistry, 2013, 13, 26-54.	2.1	74
64	Discovery of Molecular Switches That Modulate Modes of Metabotropic Glutamate Receptor Subtype 5 (mGlu₅) Pharmacology in Vitro and in Vivo within a Series of Functionalized, Regioisomeric 2- and 5-(Phenylethynyl)pyrimidines. Journal of Medicinal Chemistry, 2009, 52, 4103-4106.	6.4	72
65	Classics in Chemical Neuroscience: Fluoxetine (Prozac). ACS Chemical Neuroscience, 2014, 5, 14-23.	3.5	71
66	Discovery of a Novel Chemical Class of mGlu₅ Allosteric Ligands with Distinct Modes of Pharmacology. ACS Chemical Neuroscience, 2010, 1, 702-716.	3.5	70
67	Probing the Metabotropic Glutamate Receptor 5 (mGlu₅) Positive Allosteric Modulator (PAM) Binding Pocket: Discovery of Point Mutations That Engender a â€œMolecular Switchâ€•in PAM Pharmacology. Molecular Pharmacology, 2013, 83, 991-1006.	2.3	70
68	Synthesis and structureâ€“activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of Dorsomorphin: The discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 3248-3252.	2.2	69
69	Challenges in the development of mGluR5 positive allosteric modulators: The discovery of CPPHA. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 1386-1391.	2.2	68
70	Roles of the M1 Muscarinic Acetylcholine Receptor Subtype in the Regulation of Basal Ganglia Function and Implications for the Treatment of Parkinson's Disease. Journal of Pharmacology and Experimental Therapeutics, 2012, 340, 595-603.	2.5	64
71	M₅Receptor Activation Produces Opposing Physiological Outcomes in Dopamine Neurons Depending on the Receptor's Location. Journal of Neuroscience, 2014, 34, 3253-3262.	3.6	64
72	Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part II. Identification of the 1,3,8-triazaspiro[4,5]decan-4-one privileged structure that engenders PLD2 selectivity. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 2240-2243.	2.2	63

#	Article	IF	Citations
73	Discovery and optimization of a novel, selective and brain penetrant M1 positive allosteric modulator (PAM): The development of ML169, an MLPCN probe. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 2697-2701.	2.2	63
74	Discovery of the First M₅-Selective and CNS Penetrant Negative Allosteric Modulator (NAM) of a Muscarinic Acetylcholine Receptor: (S)-9b-(4-Chlorophenyl)-1-(3,4-difluorobenzoyl)-2,3-dihydro-1H-imidazo[2,1-a]isoindol-5(9bH)-one (ML375). Journal of Medicinal Chemistry, 2013, 56, 9351-9355.	6.4	62
75	Discovery of a Selective and CNS Penetrant Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 3 with Antidepressant and Anxiolytic Activity in Rodents. Journal of Medicinal Chemistry, 2015, 58, 7485-7500.	6.4	62
76	An mGlu5-Positive Allosteric Modulator Rescues the Neuroplasticity Deficits in a Genetic Model of NMDA Receptor Hypofunction in Schizophrenia. Neuropsychopharmacology, 2016, 41, 2052-2061.	5.4	60
77	Classics in Chemical Neuroscience: Risperidone. ACS Chemical Neuroscience, 2018, 9, 1520-1529.	3.5	60
78	mGluR4-positive allosteric modulation as potential treatment for Parkinsonâ€™s disease. Future Medicinal Chemistry, 2009, 1, 501-513.	2.3	59
79	M1-positive allosteric modulators lacking agonist activity provide the optimal profile for enhancing cognition. Neuropsychopharmacology, 2018, 43, 1763-1771.	5.4	56
80	mGlu2 and mGlu3 Negative Allosteric Modulators Divergently Enhance Thalamocortical Transmission and Exert Rapid Antidepressant-like Effects. Neuron, 2020, 105, 46-59.e3.	8.1	56
81	Inhibition of Akt with small molecules and biologics: historical perspective and current status of the patent landscape. Expert Opinion on Therapeutic Patents, 2011, 21, 1309-1338.	5.0	55
82	Classics in Chemical Neuroscience: Memantine. ACS Chemical Neuroscience, 2017, 8, 1823-1829.	3.5	55
83	mGlu ₇ potentiation rescues cognitive, social, and respiratory phenotypes in a mouse model of Rett syndrome. Science Translational Medicine, 2017, 9, .	12.4	55
84	Accelerating lead development by microwave-enhanced medicinal chemistry. Drug Discovery Today: Technologies, 2005, 2, 155-161.	4.0	53
85	Identification of Positive Allosteric Modulators VU0155094 (ML397) and VU0422288 (ML396) Reveals New Insights into the Biology of Metabotropic Glutamate Receptor 7. ACS Chemical Neuroscience, 2014, 5, 1221-1237.	3.5	53
86	The antipsychotic potential of muscarinic allosteric modulation. Drug News and Perspectives, 2010, 23, 229.	1.5	53
87	Discovery, Synthesis, and Structureâ€“Activity Relationship Development of a Series of N-4-(2,5-Dioxopyrrolidin-1-yl)phenylpicolinamides (VU0400195, ML182): Characterization of a Novel Positive Allosteric Modulator of the Metabotropic Glutamate Receptor 4 (mGlu₄) with Oral Efficacy in an Antiparkinsonian Animal Model. Journal of Medicinal Chemistry, 2011, 54, 7639-7647.	6.4	52
88	Discovery of (R)-(2-Fluoro-4-((-4-methoxyphenyl)ethynyl)phenyl) (3-Hydroxypiperidin-1-yl)methanone (ML337), An mGlu₃ Selective and CNS Penetrant Negative Allosteric Modulator (NAM). Journal of Medicinal Chemistry, 2013, 56, 5208-5212.	6.4	52
89	Phospholipase D Facilitates Efficient Entry of Influenza Virus, Allowing Escape from Innate Immune Inhibition. Journal of Biological Chemistry, 2014, 289, 25405-25417.	3.4	52
90	Chemical lead optimization of a pan Gq mAChR M1, M3, M5 positive allosteric modulator (PAM) lead. Part II: Development of a potent and highly selective M1 PAM. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 1972-1975.	2.2	51

#	Article	IF	Citations
91	Development and Antiparkinsonian Activity of VU0418506, a Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor 4 Homomers without Activity at mGlu_{2/4} Heteromers. ACS Chemical Neuroscience, 2016, 7, 1201-1211.	3.5	50
92	Parallel synthesis of N-biaryl quinolone carboxylic acids as selective M1 positive allosteric modulators. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 531-536.	2.2	48
93	Identification of Specific Ligandâ€“Receptor Interactions That Govern Binding and Cooperativity of Diverse Modulators to a Common Metabotropic Glutamate Receptor 5 Allosteric Site. ACS Chemical Neuroscience, 2014, 5, 282-295.	3.5	48
94	mGlu₅positive allosteric modulation normalizes synaptic plasticity defects and motor phenotypes in a mouse model of Rett syndrome. Human Molecular Genetics, 2016, 25, 1990-2004.	2.9	48
95	Crystal structure of the M ₅ muscarinic acetylcholine receptor. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 26001-26007.	7.1	48
96	Chemical Modulation of Mutant mGlu₁ Receptors Derived from Deleterious GRM1 Mutations Found in Schizophrenics. ACS Chemical Biology, 2014, 9, 2334-2346.	3.4	46
97	Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and l-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist. Neuropharmacology, 2015, 95, 121-129.	4.1	46
98	Re-exploration of the PHCCC Scaffold: Discovery of Improved Positive Allosteric Modulators of mGluR4. ACS Chemical Neuroscience, 2010, 1, 411-419.	3.5	45
99	Discovery, Synthesis, and Structureâ^'Activity Relationship Development of a Series of N-(4-Acetamido)phenylpicolinamides as Positive Allosteric Modulators of Metabotropic Glutamate Receptor 4 (mGlu₄) with CNS Exposure in Rats. Journal of Medicinal Chemistry, 2011, 54, 1106-1110.	6.4	45
100	Modulation of pyramidal cell output in the medial prefrontal cortex by mGluR5 interacting with CB1. Neuropharmacology, 2013, 66, 170-178.	4.1	45
101	A Novel Class of Succinimide-Derived Negative Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 1 Provides Insight into a Disconnect in Activity between the Rat and Human Receptors. ACS Chemical Neuroscience, 2014, 5, 597-610.	3.5	45
102	A Rodent Model of Traumatic Stress Induces Lasting Sleep and Quantitative Electroencephalographic Disturbances. ACS Chemical Neuroscience, 2015, 6, 485-493.	3.5	45
103	Progress in the Preparation and Testing of Glycine Transporter Type-1 (GlyT1) Inhibitors. Current Topics in Medicinal Chemistry, 2006, 6, 1883-1896.	2.1	44
104	Attenuation of Cocaine's Reinforcing and Discriminative Stimulus Effects via Muscarinic M₁ Acetylcholine Receptor Stimulation. Journal of Pharmacology and Experimental Therapeutics, 2010, 332, 959-969.	2.5	44
105	Diverse Effects on M₁ Signaling and Adverse Effect Liability within a Series of M₁ Ago-PAMs. ACS Chemical Neuroscience, 2017, 8, 866-883.	3.5	44
106	New 2016 Data and Statistics for Global Pharmaceutical Products and Projections through 2017. ACS Chemical Neuroscience, 2017, 8, 1635-1636.	3.5	44
107	Design, Synthesis, and Inâ€…Vivo Efficacy of Glycine Transporter-1 (GlyT1) Inhibitors Derived from a Series of [4-Phenyl-1-(propylsulfonyl)piperidin-4-yl]methyl Benzamides. ChemMedChem, 2006, 1, 807-811.	3.2	43
108	Chemical lead optimization of a pan Gq mAChR M1, M3, M5 positive allosteric modulator (PAM) lead. Part I: Development of the first highly selective M5 PAM. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 558-562.	2.2	43

#	Article	IF	Citations
109	Chemical inhibition of fatty acid absorption and cellular uptake limits lipotoxic cell death. Biochemical Pharmacology, 2015, 98, 167-181.	4.4	43
110	Discovery of VU0467485/AZ13713945: An M₄ PAM Evaluated as a Preclinical Candidate for the Treatment of Schizophrenia. ACS Medicinal Chemistry Letters, 2017, 8, 233-238.	2.8	43
111	Cholinergic Projections to the Substantia Nigra Pars Reticulata Inhibit Dopamine Modulation of Basal Ganglia through the M4 Muscarinic Receptor. Neuron, 2017, 96, 1358-1372.e4.	8.1	43
112	A Novel M₁ PAM VU0486846 Exerts Efficacy in Cognition Models without Displaying Agonist Activity or Cholinergic Toxicity. ACS Chemical Neuroscience, 2018, 9, 2274-2285.	3.5	43
113	Mechanisms underlying prelimbic prefrontal cortex mGlu3/mGlu5-dependent plasticity and reversal learning deficits following acute stress. Neuropharmacology, 2019, 144, 19-28.	4.1	43
114	Classics in Chemical Neuroscience: Baclofen. ACS Chemical Neuroscience, 2020, 11, 1740-1755.	3.5	43
115	Identification of Metabotropic Glutamate Receptor Subtype 5 Potentiators Using Virtual High-Throughput Screening. ACS Chemical Neuroscience, 2010, 1, 288-305.	3.5	42
116	Biotransformation of a Novel Positive Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Contributes to Seizure-Like Adverse Events in Rats Involving a Receptor Agonism-Dependent Mechanism. Drug Metabolism and Disposition, 2013, 41, 1703-1714.	3.3	42
117	Discovery of molecular switches within the ADX-47273 mGlu5 PAM scaffold that modulate modes of pharmacology to afford potent mGlu5 NAMs, PAMs and partial antagonists. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 2711-2714.	2.2	41
118	Targeting Selective Activation of M₁ for the Treatment of Alzheimerâ€™s Disease: Further Chemical Optimization and Pharmacological Characterization of the M₁ Positive Allosteric Modulator ML169. ACS Chemical Neuroscience, 2012, 3, 884-895.	3.5	41
119	Discovery of VU0409551/JNJ-46778212: An mGlu₅ Positive Allosteric Modulator Clinical Candidate Targeting Schizophrenia. ACS Medicinal Chemistry Letters, 2015, 6, 716-720.	2.8	41
120	VU0477573: Partial Negative Allosteric Modulator of the Subtype 5 Metabotropic Glutamate Receptor with In Vivo Efficacy. Journal of Pharmacology and Experimental Therapeutics, 2015, 356, 123-136.	2.5	41
121	Allosteric activation of M4 muscarinic receptors improve behavioral and physiological alterations in early symptomatic YAC128 mice. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 14078-14083.	7.1	41
122	DARK Classics in Chemical Neuroscience: Opium, a Historical Perspective. ACS Chemical Neuroscience, 2018, 9, 2503-2518.	3.5	41
123	Metabotropic glutamate receptor subtype 3 gates acute stress-induced dysregulation of amygdalo-cortical function. Molecular Psychiatry, 2019, 24, 916-927.	7.9	41
124	Convenient and General Microwave-Assisted Protocols for the Expedient Synthesis of Heterocycles. Heterocycles, 2006, 70, 655.	0.7	40
125	Relationship between In Vivo Receptor Occupancy and Efficacy of Metabotropic Glutamate Receptor Subtype 5 Allosteric Modulators with Different In Vitro Binding Profiles. Neuropsychopharmacology, 2015, 40, 755-765.	5.4	40
126	Activation of Metabotropic Glutamate Receptor 7 Is Required for Induction of Long-Term Potentiation at SC-CA1 Synapses in the Hippocampus. Journal of Neuroscience, 2015, 35, 7600-7615.	3.6	40

#	Article	IF	Citations
127	Return of D₄ Dopamine Receptor Antagonists in Drug Discovery. Journal of Medicinal Chemistry, 2017, 60, 7233-7243.	6.4	40
128	Total Synthesis and Biological Evaluation of Phidianidines A and B Uncovers Unique Pharmacological Profiles at CNS Targets. ACS Chemical Neuroscience, 2012, 3, 658-664.	3.5	39
129	Discovery of N-(4-methoxy-7-methylbenzo[d]thiazol-2-yl)isonicatinamide, ML293, as a novel, selective and brain penetrant positive allosteric modulator of the muscarinic 4 (M4) receptor. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 5084-5088.	2.2	39
130	Discovery, Synthesis, and Preclinical Characterization ofN-(3-Chloro-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-3-amine (VU0418506), a Novel Positive Allosteric Modulator of the Metabotropic Glutamate Receptor 4 (mGlu4). ACS Chemical Neuroscience, 2016, 7, 1192-1200.	3.5	39
131	Prefrontal Cortex-Mediated Impairments in a Genetic Model of NMDA Receptor Hypofunction Are Reversed by the Novel M₁ PAM VU6004256. ACS Chemical Neuroscience, 2016, 7, 1706-1716.	3.5	39
132	Classics in Chemical Neuroscience: Xanomeline. ACS Chemical Neuroscience, 2017, 8, 435-443.	3.5	39
133	Discovery, Characterization, and Effects on Renal Fluid and Electrolyte Excretion of the Kir4.1 Potassium Channel Pore Blocker, VU0134992. Molecular Pharmacology, 2018, 94, 926-937.	2.3	39
134	Discovery of Positive Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5 (mGluR5). Current Topics in Medicinal Chemistry, 2005, 5, 825-846.	2.1	38
135	Discovery of 2â€(2â€Benzoxazoyl amino)â€4â€Arylâ€5â€Cyanopyrimidine as Negative Allosteric Modulators (NAMs) of Metabotropic Glutamate Receptorâ€…5 (mGlu₅): From an Artificial Neural Network Virtual Screen to an In Vivo Tool Compound. ChemMedChem, 2012, 7, 406-414.	3.2	38
136	Allosteric modulation of Class C GPCRs: a novel approach for the treatment of CNS disorders. Drug Discovery Today: Technologies, 2013, 10, e269-e276.	4.0	38
137	Discoidin domain receptor 1 kinase activity is required for regulating collagen IV synthesis. Matrix Biology, 2017, 57-58, 258-271.	3.6	38
138	Design and Synthesis of N-Aryl Phenoxyethoxy Pyridinones as Highly Selective and CNS Penetrant mGlu₃ NAMs. ACS Medicinal Chemistry Letters, 2017, 8, 925-930.	2.8	38
139	Synthesis and SAR of analogues of the M1 allosteric agonist TBPB. Part I: Exploration of alternative benzyl and privileged structure moieties. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 5439-5442.	2.2	37
140	Evaluation of the Biosynthetic Proposal for the Synthesis of Marineosins A and B. Organic Letters, 2010, 12, 1048-1051.	4.6	37
141	Synthesis and SAR of centrally active mGlu5 positive allosteric modulators based on an aryl acetylenic bicyclic lactam scaffold. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 1350-1353.	2.2	37
142	Discovery of a selective M4 positive allosteric modulator based on the 3-amino-thieno[2,3-b]pyridine-2-carboxamide scaffold: Development of ML253, a potent and brain penetrant compound that is active in a preclinical model of schizophrenia. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 346-350.	2.2	37
143	Synthesis, SAR and Unanticipated Pharmacological Profiles of Analogues of the mGluR5 Agoâ€potentiator ADXâ€47273. ChemMedChem, 2009, 4, 505-511.	3.2	36
144	The Role of Aldehyde Oxidase and Xanthine Oxidase in the Biotransformation of a Novel Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5. Drug Metabolism and Disposition, 2012, 40, 1834-1845.	3.3	36

#	Article	IF	Citations
145	Discovery of (S)-2-Cyclopentyl-N-((1-isopropylpyrrolidin2-yl)-9-methyl-1-oxo-2,9-dihydro-1H-pyrrido[3,4-b]indole-4-carb		
	Derivatives To Target Fungal Infections: Synthesis, Biological Evaluation, and Crystallographic Analysis. Journal of Medicinal Chemistry, 2018, 61, 5679-5691.	6.4	35
159	Discovery and SAR of novel mGluR5 non-competitive antagonists not based on an MPEP chemotype. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 3209-3213.	2.2	34
160	Recent Progress on the Identification of Metabotropic Glutamate 4 Receptor Ligands and Their Potential Utility as CNS Therapeutics. ACS Chemical Neuroscience, 2011, 2, 433-449.	3.5	34
161	Unresponsive Choline Transporter as a Trait Neuromarker and a Causal Mediator of Bottom-Up Attentional Biases. Journal of Neuroscience, 2017, 37, 2947-2959.	3.6	34
162	A Versatile Enantioselective Synthesis of Azabicyclic Ring Systems: A Concise Total Synthesis of (+)â€Grandisineâ€...D and Unnatural Analogues. Chemistry - A European Journal, 2012, 18, 5826-5831.	3.3	33

#	Article	IF	Citations
163	Development of a novel, CNS-penetrant, metabotropic glutamate receptor 3 (mGlu3) NAM probe (ML289) derived from a closely related mGlu5 PAM. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 3921-3925.	2.2	33
164	Partial mGlu5 Negative Allosteric Modulators Attenuate Cocaine-Mediated Behaviors and Lack Psychotomimetic-Like Effects. Neuropsychopharmacology, 2016, 41, 1166-1178.	5.4	33
165	Design and Synthesis of mGlu₂ NAMs with Improved Potency and CNS Penetration Based on a Truncated Picolinamide Core. ACS Medicinal Chemistry Letters, 2017, 8, 919-924.	2.8	33
166	Muscarinic M5 receptors modulate ethanol seeking in rats. Neuropsychopharmacology, 2018, 43, 1510-1517.	5.4	33
167	Metabotropic Glutamate Receptor 7: A New Therapeutic Target in Neurodevelopmental Disorders. Frontiers in Molecular Neuroscience, 2018, 11, 387.	2.9	33
168	Development of a highly selective, orally bioavailable and CNS penetrant M1 agonist derived from the MLPCN probe ML071. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 6451-6455.	2.2	32
169	M 1 muscarinic activation induces long-lasting increase in intrinsic excitability of striatal projection neurons. Neuropharmacology, 2017, 118, 209-222.	4.1	32
170	Challenges in the development of an M 4 PAM in vivo tool compound: The discovery of VU0467154 and unexpected DMPK profiles of close analogs. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 171-175.	2.2	32
171	Total synthesis and biological evaluation of tambjamine K and a library of unnatural analogs. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 5207-5211.	2.2	31
172	Design of 4-Oxo-1-aryl-1,4-dihydroquinoline-3-carboxamides as Selective Negative Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 2. Journal of Medicinal Chemistry, 2015, 58, 9027-9040.	6.4	31
173	DARK Classics in Chemical Neuroscience: Phencyclidine (PCP). ACS Chemical Neuroscience, 2018, 9, 2459-2474.	3.5	31
174	Recent progress in the discovery and development of negative allosteric modulators of mGluR5. Current Opinion in Drug Discovery & Development, 2009, 12, 446-57.	1.9	31
175	A General, Enantioselective Synthesis of Protected Morpholines and Piperazines. Organic Letters, 2012, 14, 2910-2913.	4.6	30
176	Discovery of VU0409106: A negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 5779-5785.	2.2	30
177	Accelerating Precision Drug Development and Drug Repurposing by Leveraging Human Genetics. Assay and Drug Development Technologies, 2017, 15, 113-119.	1.2	30
178	Synthesis and SAR of analogs of the M1 allosteric agonist TBPB. Part II: Amides, sulfonamides and ureasâ€"The effect of capping the distal basic piperidine nitrogen. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 5443-5447.	2.2	29
179	Heterobiaryl and heterobiaryl ether derived M5 positive allosteric modulators. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 5617-5622.	2.2	29
180	Chemical Modification of the M₁ Agonist VU0364572 Reveals Molecular Switches in Pharmacology and a Bitopic Binding Mode. ACS Chemical Neuroscience, 2012, 3, 1025-1036.	3.5	29

#	Article	IF	Citations
181	Contributions of Protease-Activated Receptors PAR1 and PAR4 to Thrombin-Induced GPIIbIIIa Activation in Human Platelets. Molecular Pharmacology, 2017, 91, 39-47.	2.3	29
182	Total RNA Sequencing of Rett Syndrome Autopsy Samples Identifies the M₄ Muscarinic Receptor as a Novel Therapeutic Target. Journal of Pharmacology and Experimental Therapeutics, 2018, 365, 291-300.	2.5	29
183	Selective inhibition of M₅ muscarinic acetylcholine receptors attenuates cocaine selfâ€administration in rats. Addiction Biology, 2018, 23, 1106-1116.	2.6	29
184	Spirocyclic replacements for the isatin in the highly selective, muscarinic M1 PAM ML137: The continued optimization of an MLPCN probe molecule. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 1860-1864.	2.2	28
185	Exploration of Allosteric Agonism Structureâ€"Activity Relationships within an Acetylene Series of Metabotropic Glutamate Receptor 5 (mGlu₅) Positive Allosteric Modulators (PAMs): Discovery of 5-((3-Fluorophenyl)ethynyl)-N-(3-methyloxetan-3-yl)picolinamide (ML254). Journal of Medicinal Chemistry, 2013, 56, 7976-7996.	6.4	28
186	2013 Philip S. Portoghese Medicinal Chemistry Lectureship: Drug Discovery Targeting Allosteric Sites. Journal of Medicinal Chemistry, 2014, 57, 7485-7498.	6.4	28
187	Development of a Highly Potent, Novel M₅ Positive Allosteric Modulator (PAM) Demonstrating CNS Exposure: 1-((1H-Indazol-5-yl)sulfoneyl)-N-ethyl-N-(2-(trifluoromethyl)benzyl)piperidine-4-carboxamide (ML380). Journal of Medicinal Chemistry, 2014, 57, 7804-7810.	6.4	28
188	Discovery of VU6005649, a CNS Penetrant mGlu_{7/8} Receptor PAM Derived from a Series of Pyrazolo[1,5-a]pyrimidines. ACS Medicinal Chemistry Letters, 2017, 8, 1110-1115.	2.8	28
189	Activation of the mGlu1 metabotropic glutamate receptor has antipsychotic-like effects and is required for efficacy of M4 muscarinic receptor allosteric modulators. Molecular Psychiatry, 2020, 25, 2786-2799.	7.9	28
190	Chemical modulation of glycerolipid signaling and metabolic pathways. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2014, 1841, 1060-1084.	2.4	27
191	Preparation of Unsymmetrical 1,2,4,5-Tetrazines via a Mild Suzuki Cross-Coupling Reaction. Organic Letters, 2017, 19, 5693-5696.	4.6	27
192	mGlu1 and mGlu5 modulate distinct excitatory inputs to the nucleus accumbens shell. Neuropsychopharmacology, 2018, 43, 2075-2082.	5.4	27
193	Differential Pharmacology and Binding of mGlu₂ Receptor Allosteric Modulators. Molecular Pharmacology, 2018, 93, 526-540.	2.3	27
194	Acute Negative Allosteric Modulation of M₅ Muscarinic Acetylcholine Receptors Inhibits Oxycodone Self-Administration and Cue-Induced Reactivity with No Effect on Antinociception. ACS Chemical Neuroscience, 2019, 10, 3740-3750.	3.5	27
195	Protease-activated receptor 4 activity promotes platelet granule release and platelet-leukocyte interactions. Platelets, 2019, 30, 126-135.	2.3	27
196	Activating mGlu3 Metabotropic Glutamate Receptors Rescues Schizophrenia-like Cognitive Deficits Through Metaplastic Adaptations Within the Hippocampus. Biological Psychiatry, 2021, 90, 385-398.	1.3	27
197	Synthesis of Indole Derived Protease-Activated Receptor 4 Antagonists and Characterization in Human Platelets. PLoS ONE, 2013, 8, e65528.	2.5	27
198	Total Synthesis and Biological Evaluation of the Marine Bromopyrrole Alkaloid Dispyrin: Elucidation of Discrete Molecular Targets with Therapeutic Potential. Journal of Natural Products, 2008, 71, 1783-1786.	3.0	26

#	Article	IF	Citations
199	Synthesis and SAR of novel, 4-(phenylsulfamoyl)phenylacetamide mGlu4 positive allosteric modulators (PAMs) identified by functional high-throughput screening (HTS). Bioorganic and Medicinal Chemistry Letters, 2010, 20, 5175-5178.	2.2	26
200	Biomimetic Synthesis and Biological Evaluation of Aplidiopsamine A. Organic Letters, 2012, 14, 5808-5810.	4.6	26
201	Discovery of â€˜molecular switchesâ€™ within a GIRK activator scaffold that afford selective GIRK inhibitors. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 4562-4566.	2.2	26
202	Discovery of N-(5-Fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (VU0424238): A Novel Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Selected for Clinical Evaluation. Journal of Medicinal Chemistry, 2017, 60, 5072-5085.	6.4	26
203	A novel radioligand for glycine transporter 1: characterization and use in autoradiographic and in vivo brain occupancy studies. Nuclear Medicine and Biology, 2008, 35, 315-325.	0.6	25
204	Metabotropic glutamate receptor 5-positive allosteric modulators for the treatment of schizophrenia (2004â€“2012). Pharmaceutical Patent Analyst, 2013, 2, 93-108.	1.1	25
205	Discovery, Synthesis and Characterization of a Highly Muscarinic Acetylcholine Receptor (mAChR)â€Selective M₅â€Orthosteric Antagonist, VU0488130 (ML381): A Novel Molecular Probe. ChemMedChem, 2014, 9, 1677-1682.	3.2	25
206	Application of Parallel Multiparametric Cell-Based FLIPR Detection Assays for the Identification of Modulators of the Muscarinic Acetylcholine Receptor 4 (M4). Journal of Biomolecular Screening, 2015, 20, 858-868.	2.6	25
207	M1 Muscarinic Receptors Modulate Fear-Related Inputs to the Prefrontal Cortex: Implications for Novel Treatments of Posttraumatic Stress Disorder. Biological Psychiatry, 2019, 85, 989-1000.	1.3	25
208	Phenotypic profiling of <scp>mGlu₇</scp> knockout mice reveals new implications for neurodevelopmental disorders. Genes, Brain and Behavior, 2020, 19, e12654.	2.2	25
209	Synthesis and SAR of substituted pyrazolo[1,5-a]quinazolines as dual mGlu2/mGlu3 NAMs. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 2693-2698.	2.2	24
210	Specific Activin Receptorâ€“Like Kinase 3 Inhibitors Enhance Liver Regeneration. Journal of Pharmacology and Experimental Therapeutics, 2014, 351, 549-558.	2.5	24
211	Competition and allostery govern substrate selectivity of cyclooxygenase-2. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 12366-12371.	7.1	24
212	Acetylcholine Muscarinic M4 Receptors as a Therapeutic Target for Alcohol Use Disorder: Converging Evidence From Humans and Rodents. Biological Psychiatry, 2020, 88, 898-909.	1.3	24
213	Discovery of N-{[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]methyl}benzamides as novel, selective and potent GlyT1 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 1488-1491.	2.2	23
214	Discovery of GlyT1 inhibitors with improved pharmacokinetic properties. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 1492-1495.	2.2	23
215	(3-Cyano-5-fluorophenyl)biaryl Negative Allosteric Modulators of mGlu₅: Discovery of a New Tool Compound with Activity in the OSS Mouse Model of Addiction. ACS Chemical Neuroscience, 2011, 2, 471-482.	3.5	23
216	A general, enantioselective synthesis of 1-azabicyclo[m.n.0]alkane ring systems. Tetrahedron Letters, 2013, 54, 1645-1648.	1.4	23

#	Article	IF	Citations
217	Towards the Total Synthesis of Marineosin A: Construction of the Macrocyclic Pyrrole and an Advanced, Functionalized Spiroaminal Model. European Journal of Organic Chemistry, 2013, 2013, 4215-4218.	2.4	23
218	Anatomical localization of Ca_v3.1 calcium channels and electrophysiological effects of T-type calcium channel blockade in the motor thalamus of MPTP-treated monkeys. Journal of Neurophysiology, 2016, 115, 470-485.	1.8	23
219	State-dependent alterations in sleep/wake architecture elicited by the M4 PAM VU0467154 â€“ Relation to antipsychotic-like drug effects. Neuropharmacology, 2016, 102, 244-253.	4.1	23
220	Continued optimization of the M 5 NAM ML375: Discovery of VU6008667, an M 5 NAM with high CNS penetration and a desired short half-life in rat for addiction studies. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 1356-1359.	2.2	23
221	Effects of muscarinic M1 and M4 acetylcholine receptor stimulation on extinction and reinstatement of cocaine seeking in male mice, independent of extinction learning. Psychopharmacology, 2018, 235, 815-827.	3.1	23
222	Differential Effects of Allosteric M₁ Muscarinic Acetylcholine Receptor Agonists on Receptor Activation, Arrestin 3 Recruitment, and Receptor Downregulation. ACS Chemical Neuroscience, 2010, 1, 542-551.	3.5	22
223	Discovery and SAR of a novel series of GIRK1/2 and GIRK1/4 activators. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 5195-5198.	2.2	22
224	Total Synthesis of Stemaphylline Nâ€Oxide and Related C9aâ€Epimeric Analogues. Chemistry - A European Journal, 2013, 19, 11847-11852.	3.3	22
225	Development and Validation of a Thallium Flux-Based Functional Assay for the Sodium Channel NaV1.7 and Its Utility for Lead Discovery and Compound Profiling. ACS Chemical Neuroscience, 2015, 6, 871-878.	3.5	22
226	Discovery and optimization of a novel series of highly CNS penetrant M 4 PAMs based on a 5,6-dimethyl-4-(piperidin-1-yl)thieno[2,3- d]pyrimidine core. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 3029-3033.	2.2	22
227	Species-Specific Involvement of Aldehyde Oxidase and Xanthine Oxidase in the Metabolism of the Pyrimidine-Containing mGlu₅-Negative Allosteric Modulator VU0424238 (Auglurant). Drug Metabolism and Disposition, 2017, 45, 1245-1259.	3.3	22
228	Phospholipase D as a Therapeutic Target in Brain Disorders. Neuropsychopharmacology, 2012, 37, 301-302.	5.4	21
229	Discovery of ML326: The first sub-micromolar, selective M5 PAM. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 2996-3000.	2.2	21
230	Identification and Characterization of ML352: A Novel, Noncompetitive Inhibitor of the Presynaptic Choline Transporter. ACS Chemical Neuroscience, 2015, 6, 417-427.	3.5	21
231	Role of mGlu₅ Receptors and Inhibitory Neurotransmission in M₁ Dependent Muscarinic LTD in the Prefrontal Cortex: Implications in Schizophrenia. ACS Chemical Neuroscience, 2017, 8, 2254-2265.	3.5	21
232	The Muscarinic Acetylcholine Receptor M₅: Therapeutic Implications and Allosteric Modulation. ACS Chemical Neuroscience, 2019, 10, 1025-1034.	3.5	21
233	mGlu1 potentiation enhances prelimbic somatostatin interneuron activity to rescue schizophrenia-like physiological and cognitive deficits. Cell Reports, 2021, 37, 109950.	6.4	21
234	Recent progress in the development of mGluR4 positive allosteric modulators for the treatment of Parkinson's disease. Current Topics in Medicinal Chemistry, 2009, 9, 949-63.	2.1	21

#	Article	IF	Citations
235	3-Cyano-5-fluoro-N-arylbenzamides as negative allosteric modulators of mGlu5: Identification of easily prepared tool compounds with CNS exposure in rats. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 4390-4394.	2.2	20
236	Synthesis and biological evaluation of cremastrine and an unnatural analogue. Tetrahedron Letters, 2012, 53, 3577-3580.	1.4	20
237	Dihydrothiazolopyridone Derivatives as a Novel Family of Positive Allosteric Modulators of the Metabotropic Glutamate 5 (mGlu₅) Receptor. Journal of Medicinal Chemistry, 2013, 56, 7243-7259.	6.4	20
238	Isatin replacements applied to the highly selective, muscarinic M1 PAM ML137: Continued optimization of an MLPCN probe molecule. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 412-416.	2.2	20
239	Human Phospholipase D Activity Transiently Regulates Pyrimidine Biosynthesis in Malignant Gliomas. ACS Chemical Biology, 2015, 10, 1258-1268.	3.4	20
240	Further optimization of the M5 NAM MLPCN probe ML375: Tactics and challenges. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 690-694.	2.2	20
241	The Ecstasy and Agony of Assay Interference Compounds. Journal of Chemical Information and Modeling, 2017, 57, 387-390.	5.4	20
242	Discovery of an Orally Bioavailable and Central Nervous System (CNS) Penetrant mGlu₇ Negative Allosteric Modulator (NAM) in Vivo Tool Compound: N-(2-(1H-1,2,4-triazol-1-yl)-5-(trifluoromethoxy)phenyl)-4-(cyclopropylmethoxy)-3-methoxybenzamide (VU6012962). Journal of Medicinal Chemistry, 2019, 62, 1690-1695.	6.4	20
243	Discovery of VU6015929: A Selective Discoidin Domain Receptor 1/2 (DDR1/2) Inhibitor to Explore the Role of DDR1 in Antifibrotic Therapy. ACS Medicinal Chemistry Letters, 2020, 11, 29-33.	2.8	20
244	New Statistics on the Cost of New Drug Development and the Trouble with CNS Drugs. ACS Chemical Neuroscience, 2014, 5, 1142-1142.	3.5	19
245	PF-06827443 Displays Robust Allosteric Agonist and Positive Allosteric Modulator Activity in High Receptor Reserve and Native Systems. ACS Chemical Neuroscience, 2018, 9, 2218-2224.	3.5	19
246	Probing the binding site of novel selective positive allosteric modulators at the M1 muscarinic acetylcholine receptor. Biochemical Pharmacology, 2018, 154, 243-254.	4.4	19
247	mGlu₅ Positive Allosteric Modulators Facilitate Long-Term Potentiation via Disinhibition Mediated by mGlu₅-Endocannabinoid Signaling. ACS Pharmacology and Translational Science, 2019, 2, 198-209.	4.9	19
248	Molecule of the Month. Current Topics in Medicinal Chemistry, 2009, 9, 416-417.	2.1	19
249	Synthesis and SAR of selective muscarinic acetylcholine receptor subtype 1 (M1 mAChR) antagonists. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 885-890.	2.2	18
250	A novel class of H3 antagonists derived from the natural product guided synthesis of unnatural analogs of the marine bromopyrrole alkaloid dispyrin. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 3204-3208.	2.2	18
251	Discovery and SAR of 6-substituted-4-anilinoquinazolines as non-competitive antagonists of mGlu5. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 6623-6626.	2.2	18
252	Synthesis and SAR of novel, non-MPEP chemotype mGluR5 NAMs identified by functional HTS. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 6502-6506.	2.2	18

#	Article	IF	Citations
253	Discovery of a Highly Selective PLD2 Inhibitor (ML395): A New Probe with Improved Physiochemical Properties and Broadâ€Spectrum Antiviral Activity against Influenza Strains. ChemMedChem, 2014, 9, 2633-2637.	3.2	18
254	Effects of VU0410120, a novel GlyT1 inhibitor, on measures of sociability, cognition and stereotypic behaviors in a mouse model of autism. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2015, 61, 10-17.	4.8	18
255	Synthesis and characterization of a series of chiral alkoxymethyl morpholine analogs as dopamine receptor 4 (D4R) antagonists. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 2481-2488.	2.2	18
256	VU6010608, a Novel mGlu₇ NAM from a Series of N-(2-(1H-1,2,4-Triazol-1-yl)-5-(trifluoromethoxy)phenyl)benzamides. ACS Medicinal Chemistry Letters, 2017, 8, 1326-1330.	2.8	18
257	Sterol 14Î±-Demethylase Structure-Based Optimization of Drug Candidates for Human Infections with the Protozoan Trypanosomatidae. Journal of Medicinal Chemistry, 2018, 61, 10910-10921.	6.4	18
258	DARK Classics in Chemical Neuroscience: Carfentanil. ACS Chemical Neuroscience, 2020, 11, 3955-3967.	3.5	18
259	Design of potent GlyT1 inhibitors: in vitro and in vivo profiles. Current Opinion in Molecular Therapeutics, 2008, 10, 591-601.	2.8	18
260	MAOS protocols for the general synthesis and lead optimization of 3,6-disubstituted-[1,2,4]triazolo[4,3-b]pyridazines. Tetrahedron Letters, 2009, 50, 212-215.	1.4	17
261	Total Synthesis of (+)-7-Bromotrypargine and Unnatural Analogues: Biological Evaluation Uncovers Activity at CNS Targets of Therapeutic Relevance. ACS Chemical Neuroscience, 2011, 2, 633-639.	3.5	17
262	Continued optimization of the MLPCN probe ML071 into highly potent agonists of the hM1 muscarinic acetylcholine receptor. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 3467-3472.	2.2	17
263	A general, enantioselective synthesis of N-alkyl terminal aziridines and C2-functionalized azetidines via organocatalysis. Tetrahedron Letters, 2015, 56, 1276-1279.	1.4	17
264	Development of Novel, CNS Penetrant Positive Allosteric Modulators for the Metabotropic Glutamate Receptor Subtype 1 (mGlu₁), Based on an N-(3-Chloro-4-(1,3-dioxoisoindolin-2-yl)phenyl)-3-methylfuran-2-carboxamide Scaffold, That Potentiate Wild Type and Mutant mGlu₁ Receptors Found in Schizophrenics. Journal of Medicinal Chemistry, 2015, 58, 7959-7971.	6.4	17
265	Optimization of M 4 positive allosteric modulators (PAMs): The discovery of VU0476406, a non-human primate in vivo tool compound for translational pharmacology. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 2296-2301.	2.2	17
266	Challenges in the development of an M 4 PAM preclinical candidate: The discovery, SAR, and biological characterization of a series of azetidine-derived tertiary amides. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 5179-5184.	2.2	17
267	Contextual Fear Extinction Induces Hippocampal Metaplasticity Mediated by Metabotropic Glutamate Receptor 5. Cerebral Cortex, 2018, 28, 4291-4304.	2.9	17
268	Discovery of Novel Central Nervous System Penetrant Metabotropic Glutamate Receptor Subtype 2 (mGlu₂) Negative Allosteric Modulators (NAMs) Based on Functionalized Pyrazolo[1,5-a]pyrimidine-5-carboxamide and Thieno[3,2-b]pyridine-5-carboxamide Cores. Journal of Medicinal Chemistry, 2019, 62, 378-384.	6.4	17
269	Discovery of VU2957 (Valiglurax): An mGlu4 Positive Allosteric Modulator Evaluated as a Preclinical Candidate for the Treatment of Parkinsonâ€™s Disease. ACS Medicinal Chemistry Letters, 2019, 10, 255-260.	2.8	17
270	Synthesis and SAR of a novel metabotropic glutamate receptor 4 (mGlu4) antagonist: Unexpected â€˜molecular switchâ€™ from a closely related mGlu4 positive allosteric modulator. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 6955-6959.	2.2	16

#	Article	IF	Citations
271	Discovery and SAR of a novel series of non-MPEP site mGlu5 PAMs based on an aryl glycine sulfonamide scaffold. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 7388-7392.	2.2	16
272	Substituted 1-Phenyl-3-(pyridin-2-yl)urea Negative Allosteric Modulators of mGlu₅: Discovery of a New Tool Compound VU0463841 with Activity in Rat Models of Cocaine Addiction. ACS Chemical Neuroscience, 2013, 4, 1217-1228.	3.5	16
273	Discovery and Characterization of ML398, a Potent and Selective Antagonist of the D4Receptor within VivoActivity. ACS Medicinal Chemistry Letters, 2014, 5, 1060-1064.	2.8	16
274	Challenges in the development of an M 4 PAM preclinical candidate: The discovery, SAR, and in vivo characterization of a series of 3-aminoazetidine-derived amides. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 2990-2995.	2.2	16
275	Discovery, Structureâ€"Activity Relationship, and Biological Characterization of a Novel Series of 6-((1H-Pyrazolo[4,3-b]pyridin-3-yl)amino)-benzo[d]isothiazole-3-carboxamides as Positive Allosteric Modulators of the Metabotropic Glutamate Receptor 4 (mGlu₄). Journal of Medicinal Chemistry, 2019, 62, 342-358.	6.4	16
276	Total synthesis of Eudistomins Y1â€"Y6. Tetrahedron Letters, 2009, 50, 7067-7069.	1.4	15
277	Alzheimerâ€™s Disease: Development of Disease-Modifying Treatments Is the Challenge for Our Generation. ACS Chemical Neuroscience, 2012, 3, 804-805.	3.5	15
278	Enantioselective synthesis of C2-functionalized, N-protected morpholines and orthogonally N,Nâ€²-protected piperazines via organocatalysis. Tetrahedron Letters, 2012, 53, 1539-1542.	1.4	15
279	Neuronal ablation of p-Akt at Ser473 leads to altered 5-HT1A/2A receptor function. Neurochemistry International, 2014, 73, 113-121.	3.8	15
280	Discovery of potent and selective GIRK1/2 modulators via â€˜molecular switchesâ€™ within a series of 1-(3-cyclopropyl-1-phenyl-1H-pyrazol-5-yl)ureas. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 5102-5106.	2.2	15
281	Evaluating the Disposition of a Mixed Aldehyde Oxidase/Cytochrome P450 Substrate in Rats with Attenuated P450 Activity. Drug Metabolism and Disposition, 2016, 44, 1296-1303.	3.3	15
282	Ligand-based virtual screen for the discovery of novel M5 inhibitor chemotypes. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 4487-4491.	2.2	15
283	Lead optimization of the VU0486321 series of mGlu 1 PAMs. Part 2: SAR of alternative 3-methyl heterocycles and progress towards an in vivo tool. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 751-756.	2.2	15
284	Discovery of a novel 2,4-dimethylquinoline-6-carboxamide M 4 positive allosteric modulator (PAM) chemotype via scaffold hopping. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 4999-5001.	2.2	15
285	Co-Activation of Metabotropic Glutamate Receptor 3 and Beta-Adrenergic Receptors Modulates Cyclic-AMP and Long-Term Potentiation, and Disrupts Memory Reconsolidation. Neuropsychopharmacology, 2017, 42, 2553-2566.	5.4	15
286	Analgesic Effects of the GIRK Activator, VU0466551, Alone and in Combination with Morphine in Acute and Persistent Pain Models. ACS Chemical Neuroscience, 2019, 10, 1294-1299.	3.5	15
287	DARK Classics in Chemical Neuroscience: U-47700. ACS Chemical Neuroscience, 2020, 11, 3928-3936.	3.5	15
288	Examining the role of muscarinic M5 receptors in VTA cholinergic modulation of depressive-like and anxiety-related behaviors in rats. Neuropharmacology, 2020, 171, 108089.	4.1	15

#	Article	IF	Citations
289	Total Synthesis of Ciliatamides A-C: Stereochemical Revision and the Natural Product-Guided Synthesis of Unnatural Analogs. Organic Letters, 2008, 10, 4545-4548.	4.6	14
290	Discovery and Development of a Potent and Highly Selective Small Molecule Muscarinic Acetylcholine Receptor Subtype I (mAChR 1 or M1) Antagonist In Vitro and In Vivo Probe. Current Topics in Medicinal Chemistry, 2009, 9, 1217-1226.	2.1	14
291	N-Acyl-Nâ€²-arylpiperazines as negative allosteric modulators of mGlu1: Identification of VU0469650, a potent and selective tool compound with CNS exposure in rats. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 3713-3718.	2.2	14
292	Platelet Lipidomic Profiling: Novel Insight into Cytosolic Phospholipase A₂Î± Activity and Its Role in Human Platelet Activation. Biochemistry, 2015, 54, 5578-5588.	2.5	14
293	Chronic Traumatic Encephalopathy (CTE): A Brief Historical Overview and Recent Focus on NFL Players. ACS Chemical Neuroscience, 2017, 8, 1629-1631.	3.5	14
294	Predictions and Statistics for the Best-Selling Drugs Globally and in the United States in 2018 and a Look Forward to 2024 Projections. ACS Chemical Neuroscience, 2019, 10, 1115-1115.	3.5	14
295	Surveying heterocycles as amide bioisosteres within a series of mGlu7 NAMs: Discovery of VU6019278. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 1211-1214.	2.2	14
296	DARK Classics in Chemical Neuroscience: Gamma-Hydroxybutyrate (GHB). ACS Chemical Neuroscience, 2020, 11, 3850-3859.	3.5	14
297	Input-specific regulation of glutamatergic synaptic transmission in the medial prefrontal cortex by mGlu ₂ /mGlu ₄ receptor heterodimers. Science Signaling, 2021, 14, .	3.6	14
298	Development of novel M1 antagonist scaffolds through the continued optimization of the MLPCN probe ML012. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 5035-5040.	2.2	13
299	Tetrahydronaphthyridine and Dihydronaphthyridinone Ethers As Positive Allosteric Modulators of the Metabotropic Glutamate Receptor 5 (mGlu₅). Journal of Medicinal Chemistry, 2014, 57, 5620-5637.	6.4	13
300	ROMK inhibitor actions in the nephron probed with diuretics. American Journal of Physiology - Renal Physiology, 2016, 310, F732-F737.	2.7	13
301	Development of a Series of (1-Benzyl-3-(6-methoxypyrimidin-3-yl)-5-(trifluoromethoxy)-1H-indol-2-yl)methanols as Selective Protease Activated Receptor 4 (PAR4) Antagonists with in Vivo Utility and Activity Against Î³-Thrombin. Journal of Medicinal Chemistry, 2016, 59, 7690-7695.	6.4	13
302	Total Synthesis of Gombamide A. Organic Letters, 2016, 18, 3810-3813.	4.6	13
303	Discovery and Optimization of Potent and CNS Penetrant M₅-Preferring Positive Allosteric Modulators Derived from a Novel, Chiral N-(Indanyl)piperidine Amide Scaffold. ACS Chemical Neuroscience, 2018, 9, 1572-1581.	3.5	13
304	Structure-Activity Relationships, Pharmacokinetics, and Pharmacodynamics of the Kir6.2/SUR1-Specific Channel Opener VU0071063. Journal of Pharmacology and Experimental Therapeutics, 2019, 370, 350-359.	2.5	13
305	Modulation of arousal and sleep/wake architecture by M1 PAM VU0453595 across young and aged rodents and nonhuman primates. Neuropsychopharmacology, 2020, 45, 2219-2228.	5.4	13
306	Confronting Racism in Chemistry Journals. ACS Applied Materials & Interfaces, 2020, 12, 28925-28927.	8.0	13

#	Article	IF	Citations
307	A Duplexed High-Throughput Screen to Identify Allosteric Modulators of the Glucagon-Like Peptide 1 and Glucagon Receptors. Journal of Biomolecular Screening, 2014, 19, 847-858.	2.6	12
308	Lead optimization of the VU0486321 series of mGlu1 PAMs. Part 1: SAR of modifications to the central aryl core. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 5107-5110.	2.2	12
309	Discovery, characterization and biological evaluation of a novel (R)-4,4-difluoropiperidine scaffold as dopamine receptor 4 (D 4 R) antagonists. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 5757-5764.	2.2	12
310	Isoform selective PLD inhibition by novel, chiral 2,8-diazaspiro[4.5]decan-1-one derivatives. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 3670-3673.	2.2	12
311	Direct activation of G-protein-gated inward rectifying K+ channels promotes nonrapid eye movement sleep. Sleep, 2019, 42, .	1.1	12
312	Progress towards the synthesis of piperazimycin A: synthesis of the non-proteogenic amino acids and elaboration into dipeptides. Tetrahedron Letters, 2010, 51, 2493-2496.	1.4	11
313	Further optimization of the M1 PAM VU0453595: Discovery of novel heterobicyclic core motifs with improved CNS penetration. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 3822-3825.	2.2	11
314	Discovery and SAR of a novel series of potent, CNS penetrant M4 PAMs based on a non-enolizable ketone core: Challenges in disposition. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 4282-4286.	2.2	11
315	Identification of the minimum PAR4 inhibitor pharmacophore and optimization of a series of 2-methoxy-6-arylimidazo[2,1- b][1,3,4]thiadiazoles. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 5481-5486.	2.2	11
316	VU6007477, a Novel M1 PAM Based on a Pyrrolo[2,3-b]pyridine Carboxamide Core Devoid of Cholinergic Adverse Events. ACS Medicinal Chemistry Letters, 2018, 9, 917-922.	2.8	11
317	The effect of the EP3 antagonist DG-041 on male mice with diet-induced obesity. Prostaglandins and Other Lipid Mediators, 2019, 144, 106353.	1.9	11
318	Preparation of 1,5-Dihydropyrazolo[3â€²,4â€²:5,6]pyrano[3,4-b]pyridines via a Microwave-Assisted, Palladium-Catalyzed Regioselective Câ€“H Heteroarylation of Electron-Rich Pyrazoles. Journal of Organic Chemistry, 2019, 84, 5855-5862.	3.2	11
319	Evaluation of intravitreal topotecan dose levels, toxicity and efficacy for retinoblastoma vitreous seeds: a preclinical and clinical study. British Journal of Ophthalmology, 2022, 106, 288-296.	3.9	11
320	Discovery of the First Selective M₄ Muscarinic Acetylcholine Receptor Antagonists with in Vivo Antiparkinsonian and Antidystonic Efficacy. ACS Pharmacology and Translational Science, 2021, 4, 1306-1321.	4.9	11
321	Small molecule/ML327 mediated transcriptional de-repression of E-cadherin and inhibition of epithelial-to-mesenchymal transition. Oncotarget, 2015, 6, 22934-22948.	1.8	11
322	Progress towards small molecule menin-mixed lineage leukemia (MLL) interaction inhibitors with in vivo utility. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 2720-2725.	2.2	10
323	Lead optimization of the VU0486321 series of mGlu1 PAMs. Part 3. Engineering plasma stability by discovery and optimization of isoindolinone analogs. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 1869-1872.	2.2	10
324	Discovery of a Novel Series of Orally Bioavailable and CNS Penetrant Glucagon-like Peptide-1 Receptor (GLP-1R) Noncompetitive Antagonists Based on a 1,3-Disubstituted-7-aryl-5,5-bis(trifluoromethyl)-5,8-dihydropyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione Core. Journal of Medicinal Chemistry, 2017, 60, 1611-1616.	6.4	10

#	Article	IF	Citations
325	novel, CNS penetrant pan-muscarinic antagonists. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 3576-3581.	2.2	10
326	The discovery of VU0486846: steep SAR from a series of M1 PAMs based on a novel benzomorpholine core. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 2175-2179.	2.2	10
327	Publication Criteria and Requirements for Studies on Protein Kinase Inhibitorsâ”€What Is Expected?. Journal of Medicinal Chemistry, 2022, 65, 6973-6974.	6.4	10
328	Iterative experimental and virtual high-throughput screening identifies metabotropic glutamate receptor subtype 4 positive allosteric modulators. Journal of Molecular Modeling, 2012, 18, 4437-4446.	1.8	9
329	Optimization of an ether series of mGlu5 positive allosteric modulators: Molecular determinants of MPEP-site interaction crossover. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 6481-6485.	2.2	9
330	Octahydropyrrolo[3,4-c]pyrrole negative allosteric modulators of mGlu1. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 5091-5096.	2.2	9
331	Discovery of VU0431316: A negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 3307-3314.	2.2	9
332	A Screen of Approved Drugs Identifies the Androgen Receptor Antagonist Flutamide and Its Pharmacologically Active Metabolite 2-Hydroxy-Flutamide as Heterotropic Activators of Cytochrome P450 3A In Vitro and In Vivo. Drug Metabolism and Disposition, 2015, 43, 1718-1726.	3.3	9
333	Discovery and SAR of novel series of imidazopyrimidinones and dihydroimidazopyrimidinones as positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu5). Bioorganic and Medicinal Chemistry Letters, 2015, 25, 1310-1317.	2.2	9
334	Discovery and SAR of muscarinic receptor subtype 1 (M1) allosteric activators from a molecular libraries high throughput screen. Part 1: 2,5-Dibenzyl-2H-pyrazolo[4,3-c]quinolin-3(5H)-ones as positive allosteric modulators. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 384-388.	2.2	9
335	Lack of Antiparkinsonian Effects of Systemic Injections of the Specific T-Type Calcium Channel Blocker ML218 in MPTP-Treated Monkeys. ACS Chemical Neuroscience, 2016, 7, 1543-1551.	3.5	9
336	2015: A New Impact Factor for ACS Chemical Neuroscience and New Topline Data for Global Pharmaceutical Products. ACS Chemical Neuroscience, 2016, 7, 842-843.	3.5	9
337	N-Alkylpyrido[1â€²,2â€²:1,5]pyrazolo-[4,3-d]pyrimidin-4-amines: A new series of negative allosteric modulators of mGlu1/5 with CNS exposure in rodents. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 1894-1900.	2.2	9
338	Use of chemical probes to explore the toxicological potential of the K+/Clâ^' cotransporter (KCC) as a novel insecticide target to control the primary vector of dengue and Zika virus, Aedes aegypti. Pesticide Biochemistry and Physiology, 2018, 151, 10-17.	3.6	9
339	Discovery and characterization of N-(1,3-dialkyl-1H-indazol-6-yl)-1H-pyrazolo[4,3-b]pyridin-3-amine scaffold as mGlu4 positive allosteric modulators that mitigate CYP1A2 induction liability. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 2641-2646.	2.2	9
340	Biased M ₁ receptorâ€“positive allosteric modulators reveal role of phospholipase D in M ₁ -dependent rodent cortical plasticity. Science Signaling, 2019, 12, .	3.6	9
341	Muscarinic M₄ and M₅ receptors in the ventral subiculum differentially modulate alcohol seeking versus consumption in male alcoholâ€preferring rats. British Journal of Pharmacology, 2021, 178, 3730-3746.	5.4	9
342	A Unique Industrial â€“ Academic Collaboration Towards the Next Generation of Schizophrenia Therapeutics. Current Topics in Medicinal Chemistry, 2014, 14, 304-312.	2.1	9

#	Article	IF	Citations
343	The effects of predator odor (TMT) exposure and mGlu3 NAM pretreatment on behavioral and NMDA receptor adaptations in the brain. Neuropharmacology, 2022, 207, 108943.	4.1	9
344	Synthesis and SAR of N-(4-(4-alklylpiperazin-1-yl)phenyl)benzamides as muscarinic acetylcholine receptor subtype 1 (M1) anatgonists. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 2174-2177.	2.2	8
345	Further exploration of M1 allosteric agonists: Subtle structural changes abolish M1 allosteric agonism and result in pan-mAChR orthosteric antagonism. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 223-227.	2.2	8
346	Novel GlyT1 inhibitor chemotypes by scaffold hopping. Part 1: Development of a potent and CNS penetrant [3.1.0]-based lead. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 1067-1070.	2.2	8
347	2014 Prescription Medications in the United States: Tremendous Growth, Specialty/Orphan Drug Expansion, and Dispensed Prescriptions Continue to Increase. ACS Chemical Neuroscience, 2015, 6, 811-812.	3.5	8
348	One pot synthesis of unsymmetrical ketones from carboxylic and boronic acids via PyClU-mediated acylative Suzuki coupling. Tetrahedron Letters, 2017, 58, 898-901.	1.4	8
349	The Ecstasy and Agony of Assay Interference Compounds. ACS Chemical Neuroscience, 2017, 8, 420-423.	3.5	8
350	The Ecstasy and Agony of Assay Interference Compounds. Biochemistry, 2017, 56, 1363-1366.	2.5	8
351	Total Synthesis and Biological Evaluation of Hybrubin A. Journal of Organic Chemistry, 2017, 82, 431-437.	3.2	8
352	Discovery of a novel, CNS penetrant M4 PAM chemotype based on a 6-fluoro-4-(piperidin-1-yl)quinoline-3-carbonitrile core. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 4274-4279.	2.2	8
353	Discovery of imidazo[1,2-a]-, [1,2,4]triazolo[4,3-a]-, and [1,2,4]triazolo[1,5-a]pyridine-8-carboxamide negative allosteric modulators of metabotropic glutamate receptor subtype 5. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 4858-4866.	2.2	8
354	Beyond the Amyloid Hypothesis of Alzheimerâ€™s Disease: Tau Pathology Takes Center Stage. ACS Chemical Neuroscience, 2018, 9, 2519-2519.	3.5	8
355	New 2017 Data and Statistics for Pharmaceutical Products. ACS Chemical Neuroscience, 2018, 9, 1518-1519.	3.5	8
356	Discovery of VU6027459: A First-in-Class Selective and CNS Penetrant mGlu₇ Positive Allosteric Modulator Tool Compound. ACS Medicinal Chemistry Letters, 2020, 11, 1773-1779.	2.8	8
357	Intravitreal HDAC Inhibitor Belinostat Effectively Eradicates Vitreous Seeds Without Retinal Toxicity In Vivo in a Rabbit Retinoblastoma Model. , 2021, 62, 8.		8
358	Development of VU6019650: A Potent, Highly Selective, and Systemically Active Orthosteric Antagonist of the M₅ Muscarinic Acetylcholine Receptor for the Treatment of Opioid Use Disorder. Journal of Medicinal Chemistry, 2022, 65, 6273-6286.	6.4	8
359	Preclinical Drug Discovery Research and Training at Vanderbilt. ACS Chemical Biology, 2007, 2, 17-20.	3.4	7
360	Synthesis and biological characterization of a series of novel diaryl amide M1 antagonists. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 6923-6928.	2.2	7

#	Article	IF	Citations
361	Discovery and SAR of a novel series of metabotropic glutamate receptor 5 positive allosteric modulators with high ligand efficiency. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 3641-3646.	2.2	7
362	Further optimization of the mGlu5 PAM clinical candidate VU0409551/JNJ-46778212: Progress and challenges towards a back-up compound. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 3515-3519.	2.2	7
363	Total synthesis of actinophenanthroline A. Tetrahedron Letters, 2016, 57, 2194-2196.	1.4	7
364	Re-exploration of the mGlu1 PAM Ro 07-11401 scaffold: Discovery of analogs with improved CNS penetration despite steep SAR. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 2289-2292.	2.2	7
365	Preliminary investigation of 6,7-dihydropyrazolo[1,5- a]pyrazin-4-one derivatives as a novel series of mGlu 5 receptor positive allosteric modulators with efficacy in preclinical models of schizophrenia. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 429-434.	2.2	7
366	Discovery of MK-1832, a Kv1.5 inhibitor with improved selectivity and pharmacokinetics. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 1062-1069.	2.2	7
367	Structureâ€“Activity Relationships of Pan-Gî±_{q/11} Coupled Muscarinic Acetylcholine Receptor Positive Allosteric Modulators. ACS Chemical Neuroscience, 2018, 9, 1818-1828.	3.5	7
368	Discovery of a novel 3,4-dimethylcinnoline carboxamide M4 positive allosteric modulator (PAM) chemotype via scaffold hopping. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 126678.	2.2	7
369	In Vitro to in Vivo Translation of Allosteric Modulator Concentration-Effect Relationships: Implications for Drug Discovery. ACS Pharmacology and Translational Science, 2019, 2, 442-452.	4.9	7
370	Development of a more highly selective M1 antagonist from the continued optimization of the MLPCN Probe ML012. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 1044-1048.	2.2	6
371	Further evaluation of novel structural modifications to scaffolds that engender PLD isoform selective inhibition. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 5553-5557.	2.2	6
372	Novel GlyT1 inhibitor chemotypes by scaffold hopping. Part 2: Development of a [3.3.0]-based series and other piperidine bioisosteres. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 1062-1066.	2.2	6
373	Pharmacoeconomics and the Medicinal Chemist. ACS Medicinal Chemistry Letters, 2014, 5, 1066-1068.	2.8	6
374	cFLIP critically modulates apoptotic resistance in epithelial-to-mesenchymal transition. Oncotarget, 2017, 8, 101072-101086.	1.8	6
375	VU6005806/AZN-00016130, an advanced M4 positive allosteric modulator (PAM) profiled as a potential preclinical development candidate. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 1714-1718.	2.2	6
376	The discovery of VU0652957 (VU2957, Valiglurax): SAR and DMPK challenges en route to an mGlu4 PAM development candidate. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 342-346.	2.2	6
377	Discovery, synthesis and characterization of a series of 7-aryl-imidazo[1,2-a]pyridine-3-ylquinolines as activin-like kinase (ALK) inhibitors. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127418.	2.2	6
378	Synthesis of Substituted 6,7-Dihydro-5H-pyrrolo[2,3-c]pyridazines/pyrazines via Catalyst-Free Tandem Hydroaminationâ€“Aromatic Substitution. Journal of Organic Chemistry, 2020, 85, 6123-6130.	3.2	6

#	Article	IF	Citations
379	Identification of a Novel Allosteric Site at the M5 Muscarinic Acetylcholine Receptor. ACS Chemical Neuroscience, 2021, 12, 3112-3123.	3.5	6
380	Discovery of VU6028418: A Highly Selective and Orally Bioavailable M4 Muscarinic Acetylcholine Receptor Antagonist. ACS Medicinal Chemistry Letters, 2021, 12, 1342-1349.	2.8	6
381	Acyl dihydropyrazolo[1,5-a]pyrimidinones as metabotropic glutamate receptor 5 positive allosteric modulators. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 5115-5120.	2.2	5
382	Discovery and characterization of a novel series of N -phenylsulfonyl-1 H -pyrrole picolinamides as positive allosteric modulators of the metabotropic glutamate receptor 4 (mGlu 4). Bioorganic and Medicinal Chemistry Letters, 2016, 26, 2984-2987.	2.2	5
383	Discovery of Tricyclic Triazolo- and Imidazopyridine Lactams as M₁ Positive Allosteric Modulators. ACS Chemical Neuroscience, 2019, 10, 1035-1042.	3.5	5
384	Identification of Novel Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5 Acting at Site Distinct from 2-Methyl-6-(phenylethynyl)-pyridine Binding. ACS Chemical Neuroscience, 2019, 10, 3427-3436.	3.5	5
385	Towards a TREK-1/2 (TWIK-Related K+ Channel 1 and 2) dual activator tool compound: Multi-dimensional optimization of BL-1249. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 1601-1604.	2.2	5
386	Discovery of 4-alkoxy-6-methylpicolinamide negative allosteric modulators of metabotropic glutamate receptor subtype 5. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 47-50.	2.2	5
387	Synthesis and SAR of a series of mGlu7 NAMs based on an ethyl-8-methoxy-4-(4-phenylpiperazin-1-yl)quinoline carboxylate core. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127529.	2.2	5
388	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. ACS Applied Materials & Interfaces, 2020, 12, 20147-20148.	8.0	5
389	Confronting Racism in Chemistry Journals. Nano Letters, 2020, 20, 4715-4717.	9.1	5
390	Partial mGlu5 Negative Allosteric Modulator M-5MPEP Demonstrates Antidepressant-Like Effects on Sleep Without Affecting Cognition or Quantitative EEG. Frontiers in Neuroscience, 2021, 15, 700822.	2.8	5
391	Effects of acute and repeated administration of the selective M₄ PAM VU0152099 on cocaine versus food choice in male rats. Addiction Biology, 2022, 27, e13145.	2.6	5
392	Molecule of the Month. Current Topics in Medicinal Chemistry, 2007, 7, 739-739.	2.1	4
393	A new multi-gram synthetic route to labeling precursors for the D2/3 PET agent 18F-fallypride. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 4467-4469.	2.2	4
394	Molecule of the Month. Current Topics in Medicinal Chemistry, 2009, 9, 225-225.	2.1	4
395	Synthesis and structureâ€"activity relationships of a series of 4-methoxy-3-(piperidin-4-yl)oxy benzamides as novel inhibitors of the presynaptic choline transporter. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 1757-1760.	2.2	4
396	Optimization of a small molecule probe that restores e-cadherin expression. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 4260-4264.	2.2	4

#	Article	IF	Citations
397	The Ecstasy and Agony of Assay Interference Compounds. ACS Infectious Diseases, 2017, 3, 259-262.	3.8	4
398	Genetic and Rare Disease of the CNS. Part II: Holoprosencephaly (HPE). ACS Chemical Neuroscience, 2018, 9, 626-627.	3.5	4
399	SAR inspired by aldehyde oxidase (AO) metabolism: Discovery of novel, CNS penetrant tricyclic M4 PAMs. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 2224-2228.	2.2	4
400	Total Synthesis of Hinduchelins Aâ€“D, Stereochemical Revision of Hinduchelin A, and Biological Evaluation of Natural and Unnatural Analogues. Journal of Organic Chemistry, 2019, 84, 6459-6464.	3.2	4
401	Novel M4 positive allosteric modulators derived from questioning the role and impact of a presumed intramolecular hydrogen-bonding motif in Î²-amino carboxamide-harboring ligands. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 362-366.	2.2	4
402	Confronting Racism in Chemistry Journals. Organic Letters, 2020, 22, 4919-4921.	4.6	4
403	mGlu1-mediated restoration of prefrontal cortex inhibitory signaling reverses social and cognitive deficits in an NMDA hypofunction model in mice. Neuropsychopharmacology, 2022, 47, 1826-1835.	5.4	4
404	Molecule of the Month. Current Topics in Medicinal Chemistry, 2008, 8, 1100-1100.	2.1	3
405	Microplate-Based Assay for Identifying Small Molecules That Bind a Specific Intersubunit Interface within the Assembled HIV-1 Capsid. Antimicrobial Agents and Chemotherapy, 2015, 59, 5190-5195.	3.2	3
406	Discovery of 3-aminopicolinamides as metabotropic glutamate receptor subtype 4 (mGlu4) positive allosteric modulator warheads engendering CNS exposure and in vivo efficacy. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 2915-2919.	2.2	3
407	Optimization of the choline transporter (CHT) inhibitor ML352: Development of VU6001221, an improved in vivo tool compound. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 4637-4640.	2.2	3
408	Development and kilogram-scale synthesis of mGlu5 negative allosteric modulator VU0424238 (auglurant). Tetrahedron Letters, 2017, 58, 3554-3558.	1.4	3
409	Embarking on a 5 Year Journey to Highlight Genetic and Rare Diseases of the Central Nervous System. ACS Chemical Neuroscience, 2017, 8, 2349-2349.	3.5	3
410	Call for Papers: DARK Classics in Chemical Neuroscience. ACS Chemical Neuroscience, 2017, 8, 1812-1812.	3.5	3
411	Genetic and Rare Disease of the CNS. Part I: Fatal Familial Insomnia (FFI). ACS Chemical Neuroscience, 2017, 8, 2570-2572.	3.5	3
412	Asymmetric Synthesis of Natural and Unnatural Dibenzylbutane Lignans from a Common Intermediate. Journal of Organic Chemistry, 2019, 84, 5974-5979.	3.2	3
413	Discovery of structurally distinct tricyclic M4 positive allosteric modulator (PAM) chemotypes. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 126811.	2.2	3
414	Update to Our Reader, Reviewer, and Author Communitiesâ€”April 2020. Journal of the American Chemical Society, 2020, 142, 8059-8060.	13.7	3

#	Article	IF	Citations
415	Discovery and optimization of a novel CNS penetrant series of mGlu4 PAMs based on a 1,4-thiazepane core with in vivo efficacy in a preclinical Parkinsonian model. Bioorganic and Medicinal Chemistry Letters, 2021, 37, 127838.	2.2	3
416	Discovery of â€œMolecular Switchesâ€•within a Series of mGlu₅ Allosteric Ligands Driven by a â€œMagic Methylâ€•Effect Affording Both PAMs and NAMs with In Vivo Activity, Derived from an M₁ PAM Chemotype. ACS Bio & Med Chem Au, 2021, 1, 21-30.	3.7	3
417	New Drug Modalities in Medicinal Chemistry, Pharmacology, and Translational Science: Joint Virtual Special Issue by Journal of Medicinal Chemistry, ACS Medicinal Chemistry Letters, and ACS Pharmacology & Translational Science. Journal of Medicinal Chemistry, 2021, 64, 13935-13936.	6.4	3
418	Synthesis and pharmacological evaluation of bivalent tethered ligands to target the mGlu2/4 heterodimeric receptor results in a compound with mGlu2/2 homodimer selectivity. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127212.	2.2	3
419	mGlu ₂ and mGlu ₃ Negative Allosteric Modulators Divergently Potentiate Thalamocortical Transmission and Exert Rapid Antidepressant-Like Effects. SSRN Electronic Journal, 0, , .	0.4	3
420	Journal of Medicinal Chemistry/ACS Medicinal Chemistry Letters/Division of Medicinal Chemistry Joint Portoghese Lectureship Awards: CALL FOR NOMINATIONS. Journal of Medicinal Chemistry, 2022, 65, 1610-1611.	6.4	3
421	Clinical and Preclinical Evidence for M1 Muscarinic Acetylcholine Receptor Potentiation as a Therapeutic Approach for Rett Syndrome. Neurotherapeutics, 2022, 19, 1340-1352.	4.4	3
422	Molecule of the Month. Current Topics in Medicinal Chemistry, 2008, 8, 1553-1553.	2.1	2
423	A Call to Action on Mental Illness from the World Health Organization. ACS Chemical Neuroscience, 2016, 7, 1620-1621.	3.5	2
424	Discovery of Small-Molecule Nonfluorescent Inhibitors of Fluorogenâ€“Fluorogen Activating Protein Binding Pair. Journal of Biomolecular Screening, 2016, 21, 74-87.	2.6	2
425	Synthesis and evaluation of 4,6-disubstituted pyrimidines as CNS penetrant pan -muscarinic antagonists with a novel chemotype. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 2479-2483.	2.2	2
426	Is the Microbiome the Fifth Horseman of the Apocalypse in Drug Discovery? Implications for the Gutâ€“Brain Axis. ACS Chemical Neuroscience, 2017, 8, 1430-1430.	3.5	2
427	Discovery of 6-(pyrimidin-5-ylmethyl)quinoline-8-carboxamide negative allosteric modulators of metabotropic glutamate receptor subtype 5. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 1679-1685.	2.2	2
428	Editorsâ€™ Favorites of 2017. ACS Chemical Neuroscience, 2018, 9, 1-4.	3.5	2
429	Evaluation of Synthetic Cytochrome P₄₅₀-Mimetic Metalloporphyrins To Facilitate â€œBiomimeticâ€•Biotransformation of a Series of mGlu₅ Allosteric Ligands. ACS Omega, 2019, 4, 12782-12789.	3.5	2
430	Formal Total Synthesis of Pericoannosin A. Journal of Organic Chemistry, 2019, 84, 12187-12191.	3.2	2
431	Discovery of a novel 2,3-dimethylimidazo[1,2-a]pyrazine-6-carboxamide M4 positive allosteric modulator (PAM) chemotype. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 126812.	2.2	2
432	Update to Our Reader, Reviewer, and Author Communitiesâ€”April 2020. ACS Nano, 2020, 14, 5151-5152.	14.6	2

#	Article	IF	Citations
433	Confronting Racism in Chemistry Journals. ACS Nano, 2020, 14, 7675-7677.	14.6	2
434	Confronting Racism in Chemistry Journals. Chemical Reviews, 2020, 120, 5795-5797.	47.7	2
435	Lead optimization of the VU0486321 series of mGlu1 PAMs. Part 4: SAR reveals positive cooperativity across multiple mGlu receptor subtypes leading to subtype unselective PAMs. Bioorganic and Medicinal Chemistry Letters, 2021, 32, 127724.	2.2	2
436	The Philip S. Portoghese Journal of Medicinal Chemistry/Division of Medicinal Chemistry Joint Lectureship Awards. Journal of Medicinal Chemistry, 2021, 64, 2311-2311.	6.4	2
437	Giving Credit Where Credit Is Due: Properly Citing Relevant Prior Art. Journal of Medicinal Chemistry, 2021, 64, 5225-5225.	6.4	2
438	DARK Classics in Chemical Neuroscience: Loperamide. ACS Chemical Neuroscience, 2021, 12, 2964-2973.	3.5	2
439	Discovery of a novel class of heteroaryl-pyrrolidinones as positive allosteric modulators of the muscarinic acetylcholine receptor M1. Bioorganic and Medicinal Chemistry Letters, 2021, 47, 128193.	2.2	2
440	New Drug Modalities in Medicinal Chemistry, Pharmacology, and Translational Science: Joint Virtual Special Issue by Journal of Medicinal Chemistry, ACS Medicinal Chemistry Letters, and ACS Pharmacology & Translational Science. ACS Medicinal Chemistry Letters, 2021, 12, 1508-1509.	2.8	2
441	Positive allosteric modulators (PAMs) of the group II metabotropic glutamate receptors: Design, synthesis, and evaluation as ex-vivo tool compounds. Bioorganic and Medicinal Chemistry Letters, 2021, 50, 128342.	2.2	2
442	2021: A New Year and New Directions for the Journal of Medicinal Chemistry. Journal of Medicinal Chemistry, 2021, 64, 1-1.	6.4	2
443	Discovery and Optimization of a Novel Series of Competitive and Central Nervous System-Penetrant Protease-Activated Receptor 4 (PAR4) Inhibitors. ACS Chemical Neuroscience, 2021, 12, 4524-4534.	3.5	2
444	Molecule of the Month. Current Topics in Medicinal Chemistry, 2008, 8, 434-434.	2.1	1
445	PhRMA: Placing Prescription Drugs into Context. ACS Chemical Neuroscience, 2016, 7, 1312-1312.	3.5	1
446	Editorsâ€™ Favorites of 2016. ACS Chemical Neuroscience, 2017, 8, 1-3.	3.5	1
447	Emerging Data Strengthens the Argument That the Microbiome Is the Fifth Horseman of the Drug Discovery Apocalypse. ACS Chemical Neuroscience, 2017, 8, 1813-1813.	3.5	1
448	Torn from the Headlines: Angiostrongylus cantonensis (Rat Lungworm) Is Established in Florida. ACS Chemical Neuroscience, 2017, 8, 1632-1632.	3.5	1
449	RedH and PigC Catalyze the Biosynthesis of Hybrubins via Phosphorylation of 4â€²-Methoxy-2,2â€²-Bipyrrole-5â€²-Carbaldehyde. Applied and Environmental Microbiology, 2020, 86, .	3.1	1
450	Update to Our Reader, Reviewer, and Author Communitiesâ€”April 2020. ACS Energy Letters, 2020, 5, 1610-1611.	17.4	1

#	Article	IF	Citations
451	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Environmental Science and Technology Letters, 2020, 7, 280-281.	8.7	1
452	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Journal of Chemical Education, 2020, 97, 1217-1218.	2.3	1
453	Restoring Agonist Function at a Chemogenetically Modified M₁ Muscarinic Acetylcholine Receptor. ACS Chemical Neuroscience, 2020, 11, 4270-4279.	3.5	1
454	Confronting Racism in Chemistry Journals. Journal of Physical Chemistry Letters, 2020, 11, 5279-5281.	4.6	1
455	Confronting Racism in Chemistry Journals. ACS Central Science, 2020, 6, 1012-1014.	11.3	1
456	Confronting Racism in Chemistry Journals. Journal of the American Society for Mass Spectrometry, 2020, 31, 1321-1323.	2.8	1
457	Confronting Racism in Chemistry Journals. Crystal Growth and Design, 2020, 20, 4201-4203.	3.0	1
458	Confronting Racism in Chemistry Journals. ACS Catalysis, 2020, 10, 7307-7309.	11.2	1
459	Confronting Racism in Chemistry Journals. Journal of the American Chemical Society, 2020, 142, 11319-11321.	13.7	1
460	Chronic Traumatic Encephalopathy (CTE): A Virtual Issue Dedicated to Advances in Understanding, Diagnosing, and Potentially Treating Tauopathies. ACS Chemical Neuroscience, 2020, 11, 994-994.	3.5	1
461	Confronting Racism in Chemistry Journals. Journal of Physical Chemistry B, 2020, 124, 5335-5337.	2.6	1
462	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Crystal Growth and Design, 2020, 20, 2817-2818.	3.0	1
463	Confronting Racism in Chemistry Journals. ACS Biomaterials Science and Engineering, 2020, 6, 3690-3692.	5.2	1
464	Confronting Racism in Chemistry Journals. ACS Omega, 2020, 5, 14857-14859.	3.5	1
465	Insulin regulation of dopamine transporter activity.. FASEB Journal, 2009, 23, .	0.5	1
466	Selective Antagonism of mGlu5 Alters Sleepâ€wake and Spectral EEG and Ameliorates Behavioral Abnormalities in a Rodent Model of Traumatic Stress. FASEB Journal, 2015, 29, 615.8.	0.5	1
467	Confronting Racism in Chemistry Journals. Molecular Pharmaceutics, 2020, 17, 2229-2231.	4.6	1
468	Confronting Racism in Chemistry Journals. ACS Chemical Neuroscience, 2020, 11, 1852-1854.	3.5	1

#	Article	IF	Citations
469	Synthesis and characterization of chiral 6-azaspiro[2.5]octanes as potent and selective antagonists of the M4 muscarinic acetylcholine receptor. Bioorganic and Medicinal Chemistry Letters, 2022, 56, 128479.	2.2	1
470	NeuroChat with Dr. Abdul Mannan Baig. ACS Chemical Neuroscience, 2020, 11, 3174-3176.	3.5	1
471	A Call for Diversity Story Guest Editorials. Journal of Medicinal Chemistry, 2022, 65, 1609-1609.	6.4	1
472	A Virtual Collection Focused on Antifungal Drug Discovery. Journal of Medicinal Chemistry, 2022, , .	6.4	1
473	Molecule of the Month. Current Topics in Medicinal Chemistry, 2007, 7, 1330-1330.	2.1	0
474	Molecule of the Month. Current Topics in Medicinal Chemistry, 2007, 7, 1248-1248.	2.1	0
475	Molecule of the Month. Current Topics in Medicinal Chemistry, 2008, 8, 1158-1158.	2.1	0
476	O1â€04â€05: Selective Potentiation Of Muscarinic Acetylcholine Receptor Subtype 1 Demonstrates Efficacy And Safety In Preclinical Models Of Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P181.	0.8	0
477	ACS Chemical Neuroscience: Most Cited Papers from 2016. ACS Chemical Neuroscience, 2017, 8, 2097-2098.	3.5	0
478	ACS Chemical Neuroscience: Most Cited Papers from 2015. ACS Chemical Neuroscience, 2017, 8, 1633-1634.	3.5	0
479	Feeling Rejected? ACS Chemical Neuroscience Can Help Get Your Science to the Neuroscience Community As Quickly As Possible. ACS Chemical Neuroscience, 2017, 8, 2348-2348.	3.5	0
480	Reflections on 2016 and Projecting Forward. ACS Chemical Neuroscience, 2017, 8, 1117-1117.	3.5	0
481	A Possible Repeal of the Orphan Drug Tax Credit?. ACS Chemical Neuroscience, 2017, 8, 2569-2569.	3.5	0
482	Call for Papers: Allosteric Modulators of Drug Targetsâ€"Special Issue for 2019. ACS Chemical Neuroscience, 2018, 9, 391-391.	3.5	0
483	Welcome to the DARK Side: DARK Classics in Chemical Neuroscience. ACS Chemical Neuroscience, 2018, 9, 2286-2286.	3.5	0
484	What Papers Are People Citing and What Are People Reading?. ACS Chemical Neuroscience, 2018, 9, 2097-2098.	3.5	0
485	2018: A New Impact Factor and an Expanded Cast of Associate Editors. ACS Chemical Neuroscience, 2018, 9, 1517-1517.	3.5	0
486	NeuroChat with Professor Erin Calipari. ACS Chemical Neuroscience, 2019, 10, 2623-2624.	3.5	0

#	Article	IF	Citations
487	Further exploration of an N-aryl phenoxyethoxy pyridinone-based series of mGlu3 NAMs: Challenging SAR, enantiospecific activity and in vivo efficacy. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 2670-2674.	2.2	0
488	Total synthesis of Punicagranine. Tetrahedron Letters, 2019, 60, 150989.	1.4	0
489	NeuroChat with Professor W. Michael Caudle. ACS Chemical Neuroscience, 2019, 10, 2625-2627.	3.5	0
490	NeuroChat with Professor Catherine Abbott. ACS Chemical Neuroscience, 2019, 10, 4185-4186.	3.5	0
491	NeuroChat with Professor Philippe Derreumaux. ACS Chemical Neuroscience, 2019, 10, 3334-3334.	3.5	0
492	NeuroChat with Professor Cody Wenthur. ACS Chemical Neuroscience, 2019, 10, 2085-2086.	3.5	0
493	Total synthesis of violaceimides Aâ€“E and consideration of the reported stereochemistry. Tetrahedron Letters, 2019, 60, 151103.	1.4	0
494	Editorsâ€™ Favorites: Best of 2018. ACS Chemical Neuroscience, 2019, 10, 1-4.	3.5	0
495	NeuroChat with Professor Kathryn Commons. ACS Chemical Neuroscience, 2019, 10, 2084-2084.	3.5	0
496	Call for Papers: Strategies and Tactics in CNS Drug Synthesis. ACS Chemical Neuroscience, 2019, 10, 1116-1116.	3.5	0
497	NeuroChat with Professor Danny Winder. ACS Chemical Neuroscience, 2019, 10, 4766-4767.	3.5	0
498	NeuroChat with Martin Paulus, M.D.. ACS Chemical Neuroscience, 2019, 10, 4183-4184.	3.5	0
499	NeuroChat with Professor Corey R. Hopkins. ACS Chemical Neuroscience, 2019, 10, 4442-4443.	3.5	0
500	Confronting Racism in Chemistry Journals. ACS Pharmacology and Translational Science, 2020, 3, 559-561.	4.9	0
501	Confronting Racism in Chemistry Journals. Biochemistry, 2020, 59, 2313-2315.	2.5	0
502	Update to Our Reader, Reviewer, and Author Communitiesâ€”April 2020. ACS Biomaterials Science and Engineering, 2020, 6, 2707-2708.	5.2	0
503	Update to Our Reader, Reviewer, and Author Communitiesâ€”April 2020. ACS Central Science, 2020, 6, 589-590.	11.3	0
504	Update to Our Reader, Reviewer, and Author Communitiesâ€”April 2020. ACS Chemical Biology, 2020, 15, 1282-1283.	3.4	0

#	Article	IF	Citations
505	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. ACS Chemical Neuroscience, 2020, 11, 1196-1197.	3.5	0
506	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. ACS Earth and Space Chemistry, 2020, 4, 672-673.	2.7	0
507	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. ACS Macro Letters, 2020, 9, 666-667.	4.8	0
508	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. , 2020, 2, 563-564.		0
509	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. ACS Photonics, 2020, 7, 1080-1081.	6.6	0
510	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. ACS Pharmacology and Translational Science, 2020, 3, 455-456.	4.9	0
511	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. ACS Sustainable Chemistry and Engineering, 2020, 8, 6574-6575.	6.7	0
512	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Analytical Chemistry, 2020, 92, 6187-6188.	6.5	0
513	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Chemistry of Materials, 2020, 32, 3678-3679.	6.7	0
514	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Journal of Proteome Research, 2020, 19, 1883-1884.	3.7	0
515	Confronting Racism in Chemistry Journals. Langmuir, 2020, 36, 7155-7157.	3.5	0
516	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. ACS Applied Polymer Materials, 2020, 2, 1739-1740.	4.4	0
517	NeuroChat with Dr. Karen Gregory. ACS Chemical Neuroscience, 2020, 11, 1373-1375.	3.5	0
518	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. ACS Combinatorial Science, 2020, 22, 223-224.	3.8	0
519	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. ACS Medicinal Chemistry Letters, 2020, 11, 1060-1061.	2.8	0
520	Welcome BACK to the DARK Side: DARK Classics in Chemical Neuroscience II. ACS Chemical Neuroscience, 2020, 11, 3849-3849.	3.5	0
521	Editorial Confronting Racism in Chemistry Journals. , 2020, 2, 829-831.		0
522	ACS Pharmacology & Translational Science, Version 2.0. ACS Pharmacology and Translational Science, 2020, 3, 562-562.	4.9	0

#	Article	IF	Citations
523	Welcome to Professor Hsin-Yi Lai, the Newest Associate Editor for ACS Chemical Neuroscience. ACS Chemical Neuroscience, 2020, 11, 1519-1519.	3.5	0
524	Confronting Racism in Chemistry Journals. ACS Applied Energy Materials, 2020, 3, 6016-6018.	5.1	0
525	Confronting Racism in Chemistry Journals. Industrial & Engineering Chemistry Research, 2020, 59, 11915-11917.	3.7	0
526	NeuroChat with Research Assistant Professor Alison Axtman. ACS Chemical Neuroscience, 2020, 11, 2783-2785.	3.5	0
527	Confronting Racism in Chemistry Journals. Journal of Natural Products, 2020, 83, 2057-2059.	3.0	0
528	Confronting Racism in Chemistry Journals. ACS Medicinal Chemistry Letters, 2020, 11, 1354-1356.	2.8	0
529	Confronting Racism in Chemistry Journals. Energy & Fuels, 2020, 34, 7771-7773.	5.1	0
530	Confronting Racism in Chemistry Journals. ACS Sensors, 2020, 5, 1858-1860.	7.8	0
531	CNS Pathogens: A Special Issue of ACS Chemical Neuroscience. ACS Chemical Neuroscience, 2020, 11, 2370-2370.	3.5	0
532	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Biochemistry, 2020, 59, 1641-1642.	2.5	0
533	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Journal of Chemical & Engineering Data, 2020, 65, 2253-2254.	1.9	0
534	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Organic Process Research and Development, 2020, 24, 872-873.	2.7	0
535	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. ACS Omega, 2020, 5, 9624-9625.	3.5	0
536	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. ACS Applied Electronic Materials, 2020, 2, 1184-1185.	4.3	0
537	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Journal of Physical Chemistry C, 2020, 124, 9629-9630.	3.1	0
538	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Journal of Physical Chemistry Letters, 2020, 11, 3571-3572.	4.6	0
539	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. ACS Synthetic Biology, 2020, 9, 979-980.	3.8	0
540	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. ACS Applied Energy Materials, 2020, 3, 4091-4092.	5.1	0

#	Article	IF	Citations
541	Confronting Racism in Chemistry Journals. Journal of Chemical Theory and Computation, 2020, 16, 4003-4005.	5.3	0
542	Confronting Racism in Chemistry Journals. Journal of Organic Chemistry, 2020, 85, 8297-8299.	3.2	0
543	Confronting Racism in Chemistry Journals. Analytical Chemistry, 2020, 92, 8625-8627.	6.5	0
544	Confronting Racism in Chemistry Journals. Journal of Chemical Education, 2020, 97, 1695-1697.	2.3	0
545	Confronting Racism in Chemistry Journals. Organic Process Research and Development, 2020, 24, 1215-1217.	2.7	0
546	Confronting Racism in Chemistry Journals. ACS Sustainable Chemistry and Engineering, 2020, 8, .	6.7	0
547	Confronting Racism in Chemistry Journals. Chemistry of Materials, 2020, 32, 5369-5371.	6.7	0
548	Confronting Racism in Chemistry Journals. Chemical Research in Toxicology, 2020, 33, 1511-1513.	3.3	0
549	Confronting Racism in Chemistry Journals. Inorganic Chemistry, 2020, 59, 8639-8641.	4.0	0
550	Confronting Racism in Chemistry Journals. ACS Applied Nano Materials, 2020, 3, 6131-6133.	5.0	0
551	Confronting Racism in Chemistry Journals. ACS Applied Polymer Materials, 2020, 2, 2496-2498.	4.4	0
552	Confronting Racism in Chemistry Journals. ACS Chemical Biology, 2020, 15, 1719-1721.	3.4	0
553	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Journal of Chemical Theory and Computation, 2020, 16, 2881-2882.	5.3	0
554	Confronting Racism in Chemistry Journals. Biomacromolecules, 2020, 21, 2543-2545.	5.4	0
555	Confronting Racism in Chemistry Journals. Journal of Medicinal Chemistry, 2020, 63, 6575-6577.	6.4	0
556	Confronting Racism in Chemistry Journals. Macromolecules, 2020, 53, 5015-5017.	4.8	0
557	Confronting Racism in Chemistry Journals. Organometallics, 2020, 39, 2331-2333.	2.3	0
558	Confronting Racism in Chemistry Journals. Accounts of Chemical Research, 2020, 53, 1257-1259.	15.6	0

#	Article	IF	Citations
559	Confronting Racism in Chemistry Journals. Journal of Physical Chemistry A, 2020, 124, 5271-5273.	2.5	0
560	Confronting Racism in Chemistry Journals. ACS Energy Letters, 2020, 5, 2291-2293.	17.4	0
561	Confronting Racism in Chemistry Journals. Journal of Chemical Information and Modeling, 2020, 60, 3325-3327.	5.4	0
562	Confronting Racism in Chemistry Journals. Journal of Proteome Research, 2020, 19, 2911-2913.	3.7	0
563	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Journal of Agricultural and Food Chemistry, 2020, 68, 5019-5020.	5.2	0
564	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Journal of Physical Chemistry B, 2020, 124, 3603-3604.	2.6	0
565	Confronting Racism in Chemistry Journals. Bioconjugate Chemistry, 2020, 31, 1693-1695.	3.6	0
566	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. ACS Applied Nano Materials, 2020, 3, 3960-3961.	5.0	0
567	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Journal of Natural Products, 2020, 83, 1357-1358.	3.0	0
568	Confronting Racism in Chemistry Journals. ACS Synthetic Biology, 2020, 9, 1487-1489.	3.8	0
569	Confronting Racism in Chemistry Journals. Journal of Chemical & Engineering Data, 2020, 65, 3403-3405.	1.9	0
570	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Bioconjugate Chemistry, 2020, 31, 1211-1212.	3.6	0
571	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Journal of Chemical Health and Safety, 2020, 27, 133-134.	2.1	0
572	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Chemical Research in Toxicology, 2020, 33, 1509-1510.	3.3	0
573	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Energy & Fuels, 2020, 34, 5107-5108.	5.1	0
574	2020â€"A Year of Growth for ACS Chemical Neuroscience. ACS Chemical Neuroscience, 2020, 11, 225-225.	3.5	0
575	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. ACS Applied Bio Materials, 2020, 3, 2873-2874.	4.6	0
576	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Journal of Organic Chemistry, 2020, 85, 5751-5752.	3.2	0

#	Article	IF	Citations
577	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Journal of the American Society for Mass Spectrometry, 2020, 31, 1006-1007.	2.8	0
578	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Accounts of Chemical Research, 2020, 53, 1001-1002.	15.6	0
579	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Biomacromolecules, 2020, 21, 1966-1967.	5.4	0
580	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Chemical Reviews, 2020, 120, 3939-3940.	47.7	0
581	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Environmental Science & Technology, 2020, 54, 5307-5308.	10.0	0
582	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Langmuir, 2020, 36, 4565-4566.	3.5	0
583	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Molecular Pharmaceutics, 2020, 17, 1445-1446.	4.6	0
584	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. ACS Infectious Diseases, 2020, 6, 891-892.	3.8	0
585	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Journal of Medicinal Chemistry, 2020, 63, 4409-4410.	6.4	0
586	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Journal of Physical Chemistry A, 2020, 124, 3501-3502.	2.5	0
587	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Nano Letters, 2020, 20, 2935-2936.	9.1	0
588	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. ACS Sensors, 2020, 5, 1251-1252.	7.8	0
589	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Journal of Chemical Information and Modeling, 2020, 60, 2651-2652.	5.4	0
590	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Industrial & Engineering Chemistry Research, 2020, 59, 8509-8510.	3.7	0
591	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Inorganic Chemistry, 2020, 59, 5796-5797.	4.0	0
592	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Organometallics, 2020, 39, 1665-1666.	2.3	0
593	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Organic Letters, 2020, 22, 3307-3308.	4.6	0
594	Confronting Racism in Chemistry Journals. ACS ES&T Engineering, 2021, 1, 3-5.	7.6	0

#	Article	IF	Citations
595	Confronting Racism in Chemistry Journals. ACS ES&T Water, 2021, 1, 3-5.	4.6	0
596	Ten-Year Retrospective of the Vanderbilt Institute of Chemical Biology Chemical Synthesis Core. ACS Chemical Biology, 2021, 16, 787-793.	3.4	0
597	Giving Credit Where Credit Is Due: Properly Citing Relevant Prior Art. ACS Medicinal Chemistry Letters, 2021, 12, 669-669.	2.8	0
598	Giving Credit Where Credit Is Due: Properly Citing Relevant Prior Art. ACS Chemical Neuroscience, 2021, 12, 1465-1465.	3.5	0
599	Simplifying Submission Requirements for the Journal of Medicinal Chemistry. Journal of Medicinal Chemistry, 2021, 64, 7877-7878.	6.4	0
600	New Drug Modalities in Medicinal Chemistry, Pharmacology, and Translational Science: Joint Virtual Special Issue by Journal of Medicinal Chemistry, ACS Medicinal Chemistry Letters, and ACS Pharmacology & Translational Science. ACS Pharmacology and Translational Science, 2021, 4, 1712-1713.	4.9	0
601	Development of structurally distinct tricyclic M4 positive allosteric modulator (PAM) chemotypes - Part 2. Bioorganic and Medicinal Chemistry Letters, 2021, 53, 128416.	2.2	0
602	Characterization of novel selective positive allosteric modulators (PAMS) of the M4 muscarinic acetylcholine receptor (mAChR). FASEB Journal, 2008, 22, 714.2.	0.5	0
603	Modulation of Synaptic Transmission by G Protein Î²Î³ Subunits. FASEB Journal, 2009, 23, 583.2.	0.5	0
604	A Small Molecule Screen Identifies Novel Inhibitors of the Neuronal Kâ€Cl cotransporter KCC2. FASEB Journal, 2009, 23, 797.6.	0.5	0
605	Discovery and Characterization of a Novel Subtypeâ€Selective M1 Allosteric Agonist for the Treatment of Alzheimer's Disease. FASEB Journal, 2009, 23, 756.12.	0.5	0
606	Discovery of an inward rectifying potassium channel inhibitor with preference for Kir2.3, Kir3.X and Kir7.1. FASEB Journal, 2012, 26, 695.14.	0.5	0
607	Novel Positive Allosteric Modulators Bias Acetylcholine Signaling at Human M 4 Muscarinic Receptors. FASEB Journal, 2013, 27, 1171.4.	0.5	0
608	Effects of M1 and M4 muscarinic acetylcholine receptor positive allosteric modulators on sleep and cognition in rodents. FASEB Journal, 2013, 27, 661.8.	0.5	0
609	A Novel Approach to Cholinergic Signaling Modulation: Development and Characterization of ML352, a Novel, Noncompetitive Inhibitor of the Presynaptic Choline Transporter. FASEB Journal, 2015, 29, 932.6.	0.5	0
610	Development of novel inhibitors of swellingâ€activated LRRC8 anion channels. FASEB Journal, 2018, 32, 567.3.	0.5	0
611	Discovery, characterization, and preclinical development of a Kir4.1 (KCNJ10) inhibitor for the treatment of hypertension. FASEB Journal, 2018, 32, 829.8.	0.5	0
612	The Effects of the M 1 Muscarinic Acetylcholine Receptor Positive Allosteric Modulator VU0486846 on Cognitive Performance in Aged Nonhuman Primates. FASEB Journal, 2020, 34, 1-1.	0.5	0

#	Article	IF	Citations
613	Confronting Racism in Chemistry Journals. ACS Applied Electronic Materials, 2020, 2, 1774-1776.	4.3	0
614	Confronting Racism in Chemistry Journals. Journal of Agricultural and Food Chemistry, 2020, 68, 6941-6943.	5.2	0
615	Confronting Racism in Chemistry Journals. ACS Earth and Space Chemistry, 2020, 4, 961-963.	2.7	0
616	Confronting Racism in Chemistry Journals. Environmental Science and Technology Letters, 2020, 7, 447-449.	8.7	0
617	Confronting Racism in Chemistry Journals. ACS Combinatorial Science, 2020, 22, 327-329.	3.8	0
618	Confronting Racism in Chemistry Journals. ACS Infectious Diseases, 2020, 6, 1529-1531.	3.8	0
619	Confronting Racism in Chemistry Journals. ACS Applied Bio Materials, 2020, 3, 3925-3927.	4.6	0
620	Confronting Racism in Chemistry Journals. Journal of Physical Chemistry C, 2020, 124, 14069-14071.	3.1	0
621	Confronting Racism in Chemistry Journals. ACS Macro Letters, 2020, 9, 1004-1006.	4.8	0
622	Confronting Racism in Chemistry Journals. ACS Photonics, 2020, 7, 1586-1588.	6.6	0
623	Confronting Racism in Chemistry Journals. Environmental Science & Technology, 2020, 54, 7735-7737.	10.0	0
624	Confronting Racism in Chemistry Journals. Journal of Chemical Health and Safety, 2020, 27, 198-200.	2.1	0
625	NeuroChat with Professor Thomas E. Prisinzaro. ACS Chemical Neuroscience, 2020, 11, 3993-3994.	3.5	0
626	FAREWELL. ACS Chemical Neuroscience, 2020, 11, 3995-3995.	3.5	0
627	NeuroChat with Dr. Paul A. Newhouse. ACS Chemical Neuroscience, 2020, 11, 2900-2902.	3.5	0
628	NeuroChat with Professor Clinton E. Canal. ACS Chemical Neuroscience, 2020, 11, 3485-3487.	3.5	0
629	A Virtual Collection Focused on Antifungal Drug Discovery. ACS Infectious Diseases, 2022, , .	3.8	0
630	A Virtual Collection Focused on Antifungal Drug Discovery. ACS Medicinal Chemistry Letters, 2022, 13, 327.	2.8	0

#	Article	IF	Citations
631	Age and circadian rhythmâ€dependent effects of M ₁ muscarinic acetylcholine receptor positive allosteric modulators and donepezil on sleepâ€wake architecture and arousal. Alzheimer's and Dementia, 2021, 17, .	0.8	0
632	2022: Celebrating the 65th Publication Volume of the Journal of Medicinal Chemistry. Journal of Medicinal Chemistry, 2022, 65, 1-1.	6.4	0
633	Optimized Administration of the M₄ PAM VU0467154 Demonstrates Broad Efficacy, but Limited Effective Concentrations in Mecp2^{+/â€“} Mice. ACS Chemical Neuroscience, 2022, 13, 1891-1901.	3.5	0